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ABSTRACT
Traditional cardiovascular risk markers in mid-life are harbingers of cognitive decline,
Alzheimer’s disease and vascular dementia later in life. Normal aging, co-morbidities and
other changes connected to cognitive decline make the interpretation of the risk markers
assessed in the elderly clearly more challenging. This is the incentive for finding new
cardiovascular markers with a more consistent risk stratification capacity for cognitive
decline.
The aim of the present study was to evaluate B-type natriuretic peptide (BNP), the
Mini Mental State Examination (MMSE) score and echocardiographical measures together
with  established  cardiovascular  risk  factors  for  their  impact  on  cognitive  decline  and
mortality in the elderly general population.
The thesis is based on the Kuopio 75+ health study, a prospective population-based
stratified cohort study with 601 individuals, aged more than 75 years, from Kuopio,
Eastern Finland. The participants were examined at baseline and a follow-up visit at 5
years. Cognitive function, cardiovascular history and cardiovascular risk markers,
including BNP, were recorded for all participants, and echocardiography was carried out
in  a  sub-population of  355  individuals.   The mortality  data  is  based on a  follow-up of  a
median of 7.9 years. Of the echocardiographical measures, left ventricular (LV) mass,
ejection fraction (EF) and mitral inflow pattern (E/A) were all connected to mortality. LV
mass and EF moderately predicted cardiovascular mortality. Interestingly, an E/A < 0.75
was more connected to non-cardiovascular than cardiovascular mortality. The presence of
dementive illness was more common among individuals with an E/A < 0.75. High-density
lipoprotein was associated with EF, while BNP showed no connection to EF.
Among individuals with no dementive illness at baseline, cardiovascular markers
were evaluated for their predictive power over mortality, cognitive decline and dementia
during the follow-up. While traditional cardiovascular risk-markers and illnesses failed to
predict cognitive dysfunction, BNP was a strong predictor of all cognitive end-points. In
this sub-group an MMSE score of 18–23 together with BNP were both independent
predictors of mortality; the latter also predicted cardiovascular mortality.
The present study supports the notion that cognitive function and cardiovascular risk are
closely connected also among the elderly. BNP, a direct marker of left ventricular stress, is a
superior predictor of cognitive decline and mortality when compared to traditional risk-factors. The
connection of BNP with future dementia and cognitive decline serves as a basis for testing the
impact of antihypertensive treatment in the prevention of cognitive impairment in those with
elevated BNP.
National Library of Medicine Classification: WG 100, WM220, WT120, WT116, WG 141
Medical Subject Headings: Cardiology, Cognitive function, Aged, Echocardiography, Mortality, B-type natriuretic
peptide
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TIIVISTELMÄ
Väestön ikääntymisen myötä muistisairauksien odotetaan yleistyvän maailmanlaajuisesti.
Perinteisten sydän- ja verisuonisairauksien riskitekijöiden ilmeneminen keski-iässä on
yhdistetty kognition huononemiseen ja Alzheimerin tautiin vanhusväestössä.
Ikääntymiseen liittyvät elimistön muutokset ja iän myötä yleistyvät liitännäissairaudet
vaikuttavat sydän- ja verisuonisairauksien riskitekijöihin ja vaikeuttavat näiden
riskitekijöiden ja muistihäiriöiden yhteyden tulkintaa vanhusväestössä.
Tutkimuksemme tavoitteena oli arvioida B-tyypin natriureettisen peptidin (BNP) ja
Mini Mental State Examination (MMSE) -tutkimuksen ennustearvoa kuolleisuuden,
muistin  huononemisen  ja  dementoivien  sairauksien  suhteen  yhdessä  perinteisten  sydän-
ja verisuonisairauksien riskitekijöiden kanssa. Toisena kiinnostuksen kohteena oli
sydämen ultraäänitutkimuksessa saatavien mittaustulosten merkitys kuolleisuuden
ennustajina sekä niiden yhteys BNP:hen ja muihin sydän- ja verisuonisairauksien
riskitekijöihin.
Kuopio 75+ -tutkimus on prospektiivinen, ositettuun otantaan perustuva
väestötutkimus, johon osallistui 601 yli 75-vuotiasta kuopiolaista henkilöä. Osallistujat
tutkittiin, ja heidän kuolleisuuttaan seurattiin 7.9 (mediaani) vuoden ajan. Osallistujien
laajat demografiset tiedot, sydän- ja verisuonisairaushistoria ja -riskitekijät sekä
kognitiivinen suorituskyky olivat erityisen mielenkiinnon kohteena. BNP ja
peruslaboratoriokokeet tutkittiin. Sydämen ultraäänitutkimus tehtiin 355 satunnaisesti
valitulle osallistujalle. Viiden vuoden kuluttua lähtötilanteesta osallistujat kutsuttiin
seurantakäynnille.
Sydämen ultraäänitutkimuksen parametreista vasemman kammion massa,
ejektiofraktio (EF) ja pulssi-Doppler -tekniikalla määritetty mitraaliläpän
sisäänvirtauskuvio (E/A) ennustivat kuolleisuutta seurannassa. Vasemman kammion
massa ja EF ennustivat kohtalaisesti kuolleisuutta sydän- ja verisuonisairauksiin, kun taas
E/A < 0.75 ennusti ennen kaikkea kuolleisuutta muihin kuin sydän- ja
verisuonisairauksiin. Tämän lisäksi E/A < 0.75 assosioitui dementian ilmenemiseen. Pieni
HDL-kolesteroliarvo oli yhteydessä EF:on, kun taas BNP:llä ei ollut yhteyttä siihen.
Sydän- ja verisuonisairauksien riskitekijöiden merkitystä kuolleisuuden, muistin
huononemisen ja dementian ennustajana arvioitiin osallistujajoukossa, joilla ei ollut
dementoivaa sairautta lähtötilanteessa. Perinteisillä sydän- ja verisuonisairauksien
riskitekijöillä ei ollut yhteyttä muistin huononemiseen seurannassa, kun taas BNP ennusti
merkittävästi kaikkia kognition huononemiseen liittyviä päätetapahtumia. BNP ja MMSE
18–23 ennustivat molemmat kuolleisuutta seurannassa. Kohonnut BNP liittyi itsenäisesti
erityisesti sydän- ja verisuonitautikuolleisuuteen, kun taas MMSE 18–23 ei merkittävästi
tätä ennustanut, kun tunnetut riskitekijät otettiin huomioon.
VIII
Tuloksemme vahvistavat sitä käsitystä, että sydän- ja verisuonisairaudet ja kognition
huononeminen ovat kiinteässä yhteydessä keskenään myös vanhusväestössä ja niillä on
itsenäinen merkitys kuolleisuuden lisääjinä. Tutkimuksessamme todettu BNP:n yhteys
kognition huononemiseen ja dementian ilmenemiseen seurannassa tarjoaa
mahdollisuuden tutkia verenpainelääkityksen vaikutusta muistihäiriön ilmenemiseen ja
vaikeutumiseen potilailla, joilla on suuri BNP-pitoisuus.
Yleinen suomalainen asiasanasto: dementia, sydän-ja verisuonisairaudet, kuolleisuus, ikääntyneet,
ultraäänitutkimus, kognitio
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1 Introduction
At present, the risk of an individual to develop dementia over his or her lifetime is 20% for
men and 33% for women (Herbert et al. 2003), and globally as many as one in four persons
aged 85 years or older, representing the fastest-growing segment of the population, may
suffer from Alzheimer’s disease (AD) or another dementing illness (Ferri et al. 2005). The
aging of the population is expected to make the incidence and prevalence of various types
of dementia double every twenty years, amounting to a global figure of 81 million persons
affected by the year 2040 (Ferri et al. 2005). With no curative treatment available, measures
need to be taken to recognise the risk factor of dementia that can be modified.
The two most common forms of dementia, Alzheimer's disease (AD) and vascular
dementia (VaD), have traditionally been classified as separate entities – AD was formerly
considered a purely neurodegenerative process that causes cognitive dysfunction, whereas
VaD was defined as cognitive impairment due to vascular diseases. It has been
demonstrated recently that cardiovascular risk factors, such as diabetes, hypertension,
dyslipidaemia and metabolic syndrome, are associated with not only VaD but also AD
(Kivipelto et al. 2001; Kloppenborg et al. 2008; Xu et al. 2009).
Hypertension, hyperlipidaemia, and diabetes in middle age predispose to cognitive
impairment assessed in later life (Kivipelto et al. 2001; Kivipelto et al. 2001; Kloppenborg
et al. 2008). The impact of these risk factors on cognitive function is less clear when
measured in the elderly (Kloppenborg et al. 2008). Treatment of the cardiovascular risk
factors, such as hypertension and hyperlipidaemia, has been associated with better
cognitive function in cross-sectional studies, but the results from prospective trials have
been disappointing (McGuinness et al. 2009).
Cognitive dysfunction has been reported to be common among elderly heart failure
patients, and the level of cognitive dysfunction has been shown to associate with the level
of systolic dysfunction among heart failure patients (Zuccala et al. 1997). Natriuretic
peptides, secreted from the chambers of the heart in response to elevated stress on the
heart muscle, have been connected to cognitive function in a few cross-sectional trials
among younger populations (Gunstad et al. 2006; Feola et al. 2007; Buerger et al. 2009).
Echocardiography is widely used in diagnosing structural heart disease and dysfunction
of the heart. Several echocardiographic measures are also connected to excess mortality in
general populations (Levy et al. 1990; Gardin et al. 2001; Bella et al. 2002; Wang et al. 2003;
Kardys et al. 2009), but data has not been similarly validated among the elderly.
Severe cognitive decline and dementing illness have a remarkable impact on
mortality (Kelman et al. 1994; Larson et al. 2004), but the role of modest impairment is less
clear (Fried et al. 1998; Stump et al. 2001; Nguyen et al. 2003; Strandberg et al. 2009). BNP
has performed well as a risk marker of mortality in several high-risk groups including the
elderly (Wallen et al. 1997; Kistorp et al. 2005). Despite the accumulating evidence
concerning the pivotal role of cardiovascular burden in the development of cognitive
dysfunction, the independent predictive power of MMSE and BNP as mortality predictors
has not been studied previously.
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2.1 CARDIOVASCULAR RISK MARKERS AND COGNITION
2.1.1 Hypertension
Hypertension is generally accepted as the most potent risk factor of stroke (Kearney et al.
2005),  and  when  suffered  in  mid-life,  it  has  been  consistently  linked  with  impaired
cognitive  function  later  in  life,  irrespective  of  the  definition  of  hypertension  used  or  the
length of follow-up (Kloppenborg et al. 2008). In contrast, the studies with elderly
populations have demonstrated remarkable variation in terms of results – several have
found no association between systolic or diastolic blood pressure and cognitive decline
(Herber et al. 2004; Tervo et al. 2004), while one longitudinal study with a population aged
over 65 years, which was also the study with the longest follow-up, found high systolic
blood pressure to associate with vascular dementia (VaD), but not with Alzheimer’s
disease (AD) (Yoshitake et al. 1995). Furthermore, the Kungsholmen project with a cohort
of subjects aged 75–101 years and an average follow-up of 6 years connected cognitive
decline with high systolic blood pressure, low diastolic blood pressure and elevated pulse
pressure (Qiu et al. 2003; Qiu et al. 2005). On the other hand, longitudinal studies with
populations aged 75 years or older (Guo et al. 1996; Morris et al. 2001; Verghese et al. 2003)
and over 85 years (Ruitenberg et al. 2001) have reported a connection between low blood
pressure and impaired cognitive function.
There are several possible explanations for these seemingly contradictory findings
regarding arterial pressure and cognition. The adverse effect of high blood pressure is
explained by the established association between systolic blood pressure and endothelial
function and atherosclerosis. Chronic hypertension causes vascular pathology, leading to
cerebral hypoperfusion and hypoxemia, which appears to be the likely mediator for the
harmful effects of hypertension on cognition. The possible pathophysiological mechanism
behind the progression from chronic hypertension to regional hypoperfusion include
microvascular degeneration with altered cerebral endothelium, the proliferation of
vascular smooth muscle cells, basal lamina alterations, luminal narrowing and fibrosis.
Dysfunction of the rennin-angiotensin-aldosterone (RAA) system or the nitric oxide
pathways, both of which are key mechanisms in the development of chronic hypertension,
has  been linked with congnitive  decline  –  both directly  and through the  development  of
the said vascular changes. Furthermore, studies on mice have suggested that the
accumulation of amyloid  may be directly increased by the vascular changes induced by
hypertension (Iadecola 2004).
Low blood pressure, especially during diastole, causes hypoperfusion and
hypoxemia  in  the  brain  tissue,  which  in  turn  promotes  ischaemic  injuries  and  clinical
dementia. Among the elderly, several co-morbidities may have a simultaneous effect on
blood pressure – a previously hypertensive patient, for instance, can develop heart failure,
atrial fibrillation or aortic stenosis, which then lowers the blood pressure. Moreover, it has
become commonplace to use blood-pressure-lowering agents to treat a diversity of
cardiovascular conditions, and elderly individuals are also prone to become dehydrated,
which can, in itself, lower blood pressure detrimentally. Furthermore, it has been shown
that blood pressure begins to lower 2–3 years before the clinical diagnosis of AD, and it
further attenuates when the cognitive dysfunction deepens in AD patients (Verghese et al.
2003; Hanon et al. 2005; Qiu et al. 2005).
3Epidemiological data from several studies with large cohorts indicate that the
application of antihypertensive medications is connected with better cognitive function
(Guo et al. 1999; Veld et al. 2001). A recent prospective cohort analysis of a large
population of elderly male cardiovascular disease patients revealed that those who were
on angiotensin II receptor blockers (ARB) were significantly less likely to suffer from AD
than individuals treated with other types of antihypertensive medications. Furthermore,
the admission to a nursing home and mortality were delayed among ARB users with pre-
existing AD (Li et al. 2010). The use of lisinopril, which is the most common angiotensin-
converting enzyme inhibitor  (ACE-i),  was  found to  have a  beneficial  effect  on cognition,
but this association was not as marked. The combined use of both an ACE-i and an ARB
yielded the best prognosis with regard to cognition (Li et al. 2010).
ACE inhibitors can be divided into two categories according to their ability to
penetrate the blood-brain barrier: captopril, fosinopril, lisinopril, perindopril, ramipril and
trandolapril are potentially centrally active, while benazepril, enalapril, moexipril and
quinapril are not able to cross the blood-brain barrier and are therefore defined as non-
centrally active. A retrospective analysis from the Cardiovascular Health Study suggested
that, as opposed to other antihypertensive agents, ACE inhibitors had a protective effect
on cognition, but only with regard to substances with potential centrally active agents
(Sink et al. 2009).
 In the context of possible benefits with reference to cognitive measures and dementia
prevention, randomised hypertension treatment studies on the elderly have yielded
conflicting results (Applegate et al. 1994; Forette et al. 1998; Skoog et al. 2005; Peters et al.
2008). Only one of the studies, with the calcium-channel blocker nitrendipine as the study
drug, indicated that antihypertensive drugs might be beneficial in preventing dementia
among the elderly (Forette et al. 1998); the principal result of this study was based on 11
vs. 21 dementia cases over a follow-up of two years. A Cochrane database systematic
review which included these four trials concluded that there is no convincing evidence to
date from randomised controlled trials to the effect that lowering blood pressure in late
life prevents the development of cognitive impairment and dementia in patients with no
apparent prior cerebrovascular disease (McGuinness et al. 2009). A recent analysis from
the ONTARGET trial comparing ARB, telmisartan and the ACE inhibitor ramipril, or the
combination of these two, found no difference in cognitive decline between the groups. In
the TRANSCEND sub-study of this trial,  those intolerant to ACE inhibition were treated
blindly with either placebo or telmisartan. Disappointingly, treatment with telmisartan
did  not  have  an  impact  on  cognition  during  the  follow-up  of  5.3  years  among  5,926
participants with diabetes or cardiovascular disease (Anderson et al. 2011).
It should be pointed out that none of the randomised trials conducted to date have
included  congnitive  measures  or  a  diagnosis  of  dementia  as  a  primary  endpoint.  The
dropout rates have also been high in many of the studies, which possibly negates the effect
of the study drug on any cognitive aspects (Di Bari et al. 2001). Furthermore, as pointed
out in the Cochrane review, the use of antihypertensive medication has also been common
in the control groups, which may attenuate the true effect of the antihypertensive
treatment on cognition (McGuinness et al. 2009). Another factor possibly downplaying the
results is that the follow-up periods of the mentioned studies may have been too short to
uncover the beneficial effects on cognition. Considering these methodological
imperfections, it is obvious that randomised placebo-controlled trials using cognitive
measures and diagnosed AD and VaD as primary endpoints are required, before the effect
of antihypertensive treatment on cognition in the elderly can be properly estimated.
42.1.2 Hyperlipidaemia
A high plasma cholesterol level in mid-life is an undisputed risk factor for cognitive
dysfunction later in life (Kivipelto et al. 2001; Kivipelto et al. 2002; Whitmer et al. 2005).
On the other hand, the risk is also increased among individuals whose cholesterol levels
decrease from mid-life to late life (Solomon et al. 2007). The Mediterranean diet, known
for its favourable composition in regard to lipid metabolism and the reduction of
cardiovascular disease, has been associated with a reduction in the risk for AD (Scarmeas
et al. 2006).
Among the elderly, the association between lipids and cognition is far more obscure,
with most studies demonstrating no association between cholesterol and cognition in late
life and a few even connecting low cholesterol with cognitive dysfunction (Mielke et al.
2005). The full extent of the role of cholesterol in the pathophysiology of dementive
illnesses remains to be elucidated. In experimental studies, cholesterol has been linked
with several key aspects in the development of Alzheimer’s disease. The production of
amyloid , an essential factor in the development of AD, has been connected to cholesterol
(Figure 1), and cholesterol-lowering agents have been demonstrated to decrease amyloid 
accumulation in guinea pigs (Fassbender et al. 2001), but not in humans (Hoglund et al.
2006). Furthermore, high total cholesterol can accelerate the atherosclerotic process, which
in  turn  causes  elevated  levels  of  amyloid   protein  in  the  brain  of  an  AD  patient  and
thereby aggravates the neurodegeneration (Bodovitz et al. 1996; Simons et al. 1998).
Another pathway through which the atherosclerotic process initiated by dyslipidaemia
can facilitate cognitive dysfunction is by causing strokes and silent infarctions.
Figure 1. Suggested factors linking dyslipidaemia to cognitive capacity. Direction of effect is
indicated with either a minus or a plus sign. Please see the text for details.
The apolipoprotein gene (APOE) 4 allele is a known risk factor for cardiovascular
disease (Nieminen et al. 2008) as well as mid-life and late-life Alzheimer’s disease
(Saunders et al. 1993). The carriers of this isoform among AD patiens experience a faster
decline in their cognitive function (Cosention et al. 2008). Among cognitively normal
individuals, carries of the APOE 4 allele are at higher risk of developing a decline in their
cognitive function if cardiovascular risk-factors are present (Caselli et al. 2011). Compared
to the 2 and 3 alleles, 4 is associated with down-regulation of the LDL receptor and
5HMG-CoA,  and  these  conflicting  effects  lead,  in  aggregate,  to  higher  levels  of  LDL
cholesterol (Mahley 1988), but it is not clear if this is the mechanism explaining the
connection between APOE status and cognitive decline.
The fact that higher cholesterol has been found to have a seemingly protective effect
on cognition among the elderly could be explained by the favourable impact of cholesterol
on neuronal plasticity (Pfrieger 2003). Furthermore, weight loss is also common in AD and
has been associated with lower blood lipids (Nourhashemi et al. 2008). A decrease in
cholesterol from mid-life to late life, which has been shown to be a risk factor for
dementia, might actually be a consequence of the pathological mechanisim that leads to
dementive illness (Solomon et al. 2007) – the connection between high cholesterol and
better cognitive function would then be flipside of the same phenomenon. It has been
speculated that the anti-oxidant activities of the cholesterol could also potentially explain
the association (Smith 1991). The systemic lipid metabolism and transport in human is
separated from the central nervous system as the lipid particles are unable to cross the
blood-brain barrier (Dietschy 2009). Cholesterol in peripheral circulation is bound to
lipoproteins making any direct effect of plasma cholesterol on cognitive function unlikely
(Hayashi 2011).
Cholesterol metabolism is closely associated with the progression of atherosclerosis
and cardiovascular disease. Cholesterol-lowering with statins has been established as a
successful stroke and cardiovascular disease prevention strategy (Pedersen et al. 1994; Sacs
et al. 1996; Kerola et al. 2010), and several epidemiological studies have linked their use
with a reduced risk of cognitive disorders both in mid-life and among the elderly (Jick et
al. 2000; Haag et al. 2009). Two randomised placebo-controlled trials have been completed
with focus on the efficacy of statin therapy in the prevention of cognitive deterioration
among AD patients. In the larger of the two (n=640), atorvastatin was administered for 72
weeks to mild-to-moderate AD patients, with no significant benefits in terms of cognitive
measures (Feldman et al. 2010). The results of the second trial, the CLASP (n=403), have
not  yet  been  published,  but  according  to  the  lead  investigator  of  the  trial,  there  was  no
difference in primary or secondary outcomes between the simvastatin ajnd placebo groups
(personal communication with Dr. Mary Sano, lead investigator of CLASP).
 On the basis of the knowledge currently available, statin treatment cannot be
recommended for the prevention of dementia. The study protocols of large statin trials
from the last two decades have unfortunately not included the measurement of cognition
(Pedersen et al. 1994; Sacks et al. 1996), and the potential benefits of statin therapy
commenced in  mid-life  in  regard to  cognitive  function remain to  be  addressed in  future
randomised trials.
2.1.3 Diabetes
Diabetes is exceedingly common among elderly populations – in 1996, the Rotterdam
study reported a prevalence of 11.5% in a population aged 55 to 90 years (Ott et al. 1996),
and recent data from the U.S. indicates that the prevalence of type II diabetes alone is as
high as 23% among individuals aged over 60 years (U.S. Department of Health and
Human Services 2005). Diabetes was first connected with cognitive impairment by Miles et
al. as early as in 1922 when they demonstrated the inferior performance of diabetics in
memory, arithmetic and psychomotor tests (Miles et al. 1922). Over the last two decades,
multiple studies have investigated the potential association between diabetes and different
forms of dementia as well as cognitive impairment among middle-aged individuals.
Diabetes may contribute by accelerating several processes involved in the aging of the
brain, such as oxidative stress, the accumulation of glycosylation and end products,
microvascular dysfunction as well as changes in cerebral glucose and insulin metabolism
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overwhelming body of evidence has established that diabetes, hyperinsulinaemia and
insulin resistance among the middle-aged all predict dementia, AD and VaD (Luchsinger
et al. 2004; Kloppenborg et al. 2008; Ronnemaa et al. 2008).
Studies with elderly populations have confirmed that diabetes continues to associate
with cognitive decline after an individual reaches the age of 65 years (Luchsinger et al.
2007; Xu et al. 2009). Roberts et al. found that a diagnosis of diabetes per se was not a risk
factor among subjects aged 70–89 years, whereas the complications of diabetes, the need
for insulin treatment and an early onset of the diabetes all predicted cognitive impairment
(Roberts et al. 2008). Furthermore, a history of severe hypoglycaemic episodes has been
associated with an increase in the risk of dementia among type II diabetics aged over 55
(mean 65) years (Whitmer et al. 2009).
White  matter  changes  are  a  common  finding  in  brain  imaging  among  elderly
populations (de Leeuw et al. 2001), and this degenerative finding has been shown to
associate with cognitive dysfunction, dementia and AD (Ylikoski et al. 1993; Kuller et al.
2003; Silbert et al. 2009). One recent study on a population with white matter changes
reported diabetes to be the only cardiovascular risk marker predicting dementia (Verdelho
et al. 2010).
There are several potential mechanisms connecting diabetes or hyperinsulinaemia
with cognition (Figure 2). Diabetes is known to predispose to atherosclerotic
cerebrovascular disease, which in turn may cause white matter changes of the subcortex as
well as brain ischaemia and infarction. These manifestations are all well established as risk
factors for dementia, and they are more commonly found in the brains of diabetics
(Manschot et al. 2007). One cross-sectional study concluded that only hyperinsulinaemia,
not type II diabetes, was independently connected to cognitive dysfunction (Vanhanen et
al. 1999), while a prospective study among older women with a mean age of 66 years
demonstrated that mildly hyperglycaemic subjects were at a higher risk of developing
cognitive dysfunction as opposed to their normoglycaemic counterparts (Yaffe et al. 2004).
Figure 2. Suggested factors relating diabetes and hyperinsulinaemia to cognitive function. All
the factors are risk factors for cognitive impairment. Please see the text for details.
7Several studies have suggested that, in addition to atherogenesis, diabetes may have
a more direct connection to dementia (Ott et al. 1996; Leibson et al. 1997), although there
has been a deree of variation in the results (Ebly et al. 1995; Di Carlo et al. 2000). Oxidative
stress or protein glycosylation can predispose diabetics to dementia (Biessels 1999). The
accumulation of amyloid  and hyperphosphorylated tau protein, which are essential
components of AD, has been linked with an insulin signalling defect (de la Monte et al.
2005). Hyperinsulinaemia may also have an adverse effect on the hippocampus, which is
the part of the brain that is known to be the first to be affected in AD; the adverse effect
may be mediated by insulin receptors in the hippocampus (Park 2001). Insulin-degrading
enzyme in the brain lowers the extracellular level of amyloid  (Vekrellis et al. 2000), and
this beneficial effect is inhibited by insulin (Farris et al. 2003). Furthermore, it has been
demonstrated that hyperinsulinaemia increases amyloid  levels in the cerebrospinal fluid
of healthy adults (Fishel et al. 2005). Diabetes is also associated with elevated
concentrations of inflammatory factors – e.g., C-reactive protein (CRP), interleukin-6,
tumour-necrosis factor- and reactive oxygen species – which have also been shown to
augment the risk of AD (Haan 2006).
Several studies have established an association between diabetes and cognitive
decline, but the reports addressing the potential effect of diabetes treatment on cognition
have  been  sparse  and  the  results  so  far  have  not  been  promising.  Two  smaller  trials
demonstrated some benefit from more aggressive treatment of hyperglycaemia in elderly
patients as regards cognition during a short follow-up of 6 (Naor et al. 1997) and 24 weeks
(Ryan et al. 2006). The largest published trial, ADVANCE, assessed the benefits of
intensive vs. standard glucose lowering therapy in more than 11,140 type II diabetics aged
55 years or older; during the 5-year follow-up, no significant difference in diagnosed
dementia or cognitive decline was observed between the groups (Patel et al. 2008).
In theory, the insulin sensitizer rosiglitazone could have a favourable effect on
cognition  in  AD,  based  on  the  mechanisms  described  above.  It  has  shown  promising
results in early AD (Watson et al. 2005), although this only applied to carriers of APOE 4
allele in another study (Risner et al. 2006). In a larger 6-month interventional trial where
patients with mild to moderate AD were treated with rosiglitazone, however, no benefit
was  observed  in  regard  to  cognition  regardless  of  the  APOE  status  (Gold  et  al.).  In  fact,
rosiglitazone  has  been  withdrawn  from  clinical  use  on  the  European  market  due  to  the
increased cardiovascular risk induced by its use (European Medicines Agency 2010).
As a conclusion, congnitive status has unfortunately not been followed routinely in
large diabetes treatment trials. Therefore, the effect of longer-term treatment for
hyperglycaemia on cognition remains to be settled.
2.1.4 Adiposity
In epidemiological studies, the most commonly used indicator for assessing excess
body  fat  is  the  body  mass  index  (BMI).  The  definition  of  “overweight"  is  a  BMI  of  25–
29.9kg/m², and individuals with a BMI of 30 kg/m² or more are categorized as “obese”.
However, central obesity measured by waist circumference would probably provide a
more accurate estimate of adiposity than BMI (Mueller et al. 1991).
Obesity, overweight and central obesity in mid-life have been consistently linked
with late-life cognitive impairment, Alzheimer’s disease and dementia (Gustafson et al.
2003; Kivipelto et al. 2005; Whitmer et al. 2005; Gustafson et al. 2009), but weight loss or
lowering the BMI during follow-up has also been uniformly associated with a decline in
cognitive function (Barrett-Connor et al. 1998; Stewart et al. 2005; Johnson et al. 2006).
Knopman et al. found that the weight loss preceding dementia can start decades before the
onset of clinical illness (Knopman et al. 2007).
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association of adiposity with cognitive decline; on the one hand, lower BMI has been
connected with cognitive dysfunction (Nourhashemi et al. 2003; Atti et al. 2008), but on the
other, a study by Luchsinger et al. with a population aged less than 76 years revealed that
the association between BMI and dementia resembled a U-shaped curve, with an older
population demonstrating an inverse association (Luchsinger et al. 2007).
Metabolic syndrome has been established as an independent risk factor for
cardiovascular disease and mortality, and it has also been associated with cognitive
decline in several studies with varying populations (Yaffe et al. 2004; Yaffe et al. 2007).
Two studies found a link between metabolic syndrome and cognitive decline only among
older women (Vanhanen et al. 2006; van den Berg et al. 2007), while the impact on
cognition was possibly attenuated among men (Vanhanen et al. 2006; van den Berg et al.
2007). The role of metabolic syndrome as a contributor in cognitive decline among older
women was subsequently reaffirmed in a large study by Yaffe et al. (Yaffe et al. 2009).
The mechanisms at play in regard to the association between adiposity and cognitive
impairment remain to be fully elucidated, but several plausible patwhways can be
mentioned. As related risk markers for cerebrovascular disease and stroke, which
predispose to dementia. adiposity, diabetes, dyslipidaemia and hypertension may have an
indirect role in cognitive decline.  Furthermore, hyperinsulinaemia is also common among
individuals with adiposity and metabolic syndrome, and as discussed above, insulin and
hyperinsulinaemia may play a direct role in the development of AD.
Several suggestions have been proposed as an explanation for the inverse association
between adiposity and cognitive dysfunction among the elderly. Firstly, patients with AD
begin  to  suffer  from  a  memory  deficit  in  the  very  early  stages  of  the  disease  and  can
simply forget to eat, which leads to malnourishment. In fact, a recent study suggested that
the weight loss during early AD is caused by a reduction in lean body mass rather than fat
tissue (Burns et al. 2010). Dementia patients are physically less active than their healthy
peers, which could explain the reduction in muscle mass, and insulin, as an anabolic
substance linked with AD, may act as a mediator in this catabolic process occurring both
in the musculature and in the brain (Burns et al. 2010).
Fat tissue is metabolically active and produces adipokines and cytokines. One of the
adipokines, namely leptin, has been established to regulate food intake and energy
balance,  and  the  level  of  leptin  in  the  circulation  is  directly  related  to  the  amount  of  fat
tissue in the body (Friedman et al. 1998). In addition to its effect on the hypothalamic
energy balance, leptin directly influences the hippocampus, which is the area of the brain
that is first affected in AD (Harvey et al. 2006). Leptin administration has been discovered
to enhance memory processing in mice – and in terms of the possible mechanisms behind
this phenomenon, leptin is also known to regulate amyloid  levels (Fewlass et al. 2004). A
study from the Framingham cohort revealed lower levels of leptin to be predictive of AD,
dementia and the progression of pathological changes detected in magnetic resonance
imaging during the follow-up, which suggests a direct protective effect of leptin on
cognition (Lieb et al. 2009).
2.1.5 Smoking
Smoking has been well established as an independent cardiovascular risk factor, and it has
also been linked with white matter changes, brain atrophy and a decline in perfusion
(Meyer et al. 1999). Nicotine is an acetylcholine receptor antagonist and could potentially
upregulate these receptors in the central nervous system (Murray et al. 2002). The amount
of acetylcholine receptors is thought to decline with aging; a shortage of these receptors is
evident in AD and other forms of dementia, making room for speculations as to a possible
9favourable effect of nicotine, mostly consumed with tobacco, on cognition (Court et al.
2003).
In earlier studies, cigarette smoke was indeed suggested to have a protective effect
against AD, but subsequent analyses have revealed this notion to have been largely due to
selection bias (Hernan et al. 2008) and the influence of the tobacco industry as a source of
financing for research (Cataldo et al. 2010). A meta-analysis of 23 prospective studies on
the effect of smoking on dementia concluded that current smoking is clearly a risk factor
for AD and possibly also for VaD and other forms of dementia – specifically, smokers
were found to be at a 1.59-fold risk (95% confidence interval, 1.15–2.20) of AD and a 1.35-
fold risk (0.9–1.59) of VaD in comparison to those who had never smoked (Peters et al.
2008).  The result  of  this  meta-analysis  was  confirmed and the  impact  of  smoking on the
occurrence of VaD clarified in a recent study (Rusanen et al. 2011). In a cohort of 21,123
individuals, heavy smokers had an over 2-fold risk for AD and VaD during a mean follow-
up of 23 years.
2.2 B-TYPE NATRIURETIC PEPTIDE
2.2.1 B-type natriuretic peptide
Atrial natriuretic peptide (ANP) was discovered 30 years ago (de Bold et al. 1981). Later,
the existence of B-type natriuretic peptide (BNP) was demonstrated (Sudoh et al. 1988).
The discovery of these two cardiac peptides has launched a huge area of investigation
concentrating on their synthesising, release and action. BNP was originally isolated from
porcine brain extracts (hence the other name, brain natriuretic peptide), but its
concentrations in the brain are actually very low or, in some species such as in the rat,
even undetectable (Ogawa et al. 1990).
The cardiac natriuretic peptides are released from the chambers of the heart mainly
due to  stress  of  the  myocardial  wall,  ANP from the  atrium and BNP from the  ventricles
(Yasue et al. 1994). Myocardial ischaemia and endocrine modulation by other hormones
and cytokines can also enhance peptide secretion. BNP is stored in myocytes as its
precursor, proBNP, in the left atrium and ventricle. When secreted, proBNP is cleaved into
two fragments, the active carboxyterminal fragment of BNP and the inactive N-terminal
proBNP (NT-proBNP). The secretion and cleavage of proANP into inactive N-terminal
proANP  (NT-proANP)  and  ANP  takes  place  in  a  similar  fashion.  The  main  source  of
active BNP is rapid gene expression with de novo synthesis of the peptide, and only small
amounts are stored in the secretory granules. Normally, BNP is released from both the
atrium and the ventricle, but in heart failure patients the main source of BNP seems to be
the ventricular wall (Daniels et al. 2007; Richards 2007).
BNP  is  a  natural  antagonist  of  the  (RAA)  system,  and  its  role  as  a  fluid  balance
regulator seems to be of greater importance in patients under haemodynamic stress such
as heart failure. Therefore, the physiological actions of BNP include a decrease in vascular
resistance and central venous pressure as well as an increase in natriuresis. Thus, the
resulting effect is an increase in cardiac output and decrease in blood volume. In addition,
it  inhibits  the  sympathetic  nervous  system  and  pathophysiological  mechanisms,  causing
ventricular and vascular hypertrophy and remodelling. BNP is also known to have a
beneficial effect on vascular endothelial dysfunction caused by atherosclerosis.
(Vuolteenaho et al. 2005; Daniels et al. 2007; Richards 2007)
BNP has specific receptors situated in the cell membrane, mediating its biological
actions. The mediating receptors are called “membrane bound natriuretic peptide
receptors” (NPR). NPR-A preferentially binds ANP and BNP. NPR-C mediates the
removal  of  natriuretic  peptides  from  blood  through  the  kidneys.  BNP  is  cleared  from
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plasma by means of receptor-binding and proteolysis by a specific enzyme, neutral
peptidase, whereas NT-proBNP is cleared through the kidneys without proteolysis. Due to
differences in the clearance, the half-life of BNP in plasma is 20 minutes, whereas the half-
life of NT-proBNP is 120 minutes and, similarly, the plasma values of NT-proBNP are
approximately six times higher than BNP values (Vuolteenaho et al. 2005; Daniels et al.
2007; Richards 2007).
Levels of cardiac peptides can be measured from the blood and have been thoroughly
investigated especially in the context of heart failure. ANP has a short half life and is
unstable  when  stored.  NT-proANP,  BNP  and  NT-proBNP  are  known  to  be  more  stable
and therefore better suitable for the assessment of cardiac patients. Women have higher
levels  of  circulating NT-proANP,  NT-proBNP and BNP,  possibly  due to  the  influence  of
oestrogen (Redfield et al. 2002; Loke et al. 2003). NT-proANP, BNP and NT-proBNP levels
correlate positively with age, although the effect on BNP may be smaller (Redfield et al.
2002; Loke et al. 2003). In obese patients the natriuretic peptide levels seem to be lower
(Mehra et al. 2004; Wang et al. 2004). Hyperthyroidism and anaemia are known to
associate with natriuretic peptide levels. Higher heart rate seems to be correlated with
lower levels of all three peptides. Renal insufficiency is associated hypertension, higher
left ventricular mass and heart failure, all leading to elevated levels of natriuretic peptides.
Renal insufficiency can also attenuate the clearance of the NT-proBNP and NPR-C, leading
to falsely elevated levels of BNP and NT-BNP (Vuolteenaho et al. 2005; Daniels et al. 2007;
Richards 2007).
2.2.2 B-type natriuretic peptide and echocardiographic measures
 Normal BNP and NT-proBNP levels are known to exclude moderate to severe systolic
dysfunction in untreated patients with symptoms suggestive of heart failure, and the
measurement of plasma-BNP and p-NT-proBNP is widely recommended in this context
(Tang et al. 2007). The level of BNP is also known to associate with the degree of diastolic
dysfunction (Yamaguchi et al. 2004), level of left ventricular hypertrophy (Luchner et al.
2000), presence of atrial fibrillation (Ellinor et al. 2005) and the degree of heart valve
disease (Daniels et al. 2007). In community screening, natriuretic peptides have been tested
as a screening test for echocardiography, but their ability to identify patients with cardiac
abnormalities in larger low-morbidity populations has been suboptimal (Vasan et al.
2002). Their use has been suggested to be cost-effective as a screening test for
echocardiography among high-risk populations including the elderly (Heidenreich et al.
2004).  BNP measures have also proven to associate inversely with the effective therapy of
systolic heart failure, such as ACE inhibitors, ARBs and spironolactone (Inoko et al. 2001;
Latini et al. 2002; Macdonald et al. 2004). This is probably due to a reduction in filling
pressures and a reversal of pathological remodelling following a neurohormonal blockade
of the RAA system. Changes in the level of natriuretic peptides, when treated with beta-
adrenergic blockers, have been somewhat mixed, showing raised levels in the short term,
but reduction in the natriuretic peptide levels in long-term treatment (Latini et al. 2002;
Yoshizawa et al. 2004). Although some studies have suggested that the measurement of
natriuretic peptides could be used in guiding a specific therapy of heart failure in clinical
practice, this is not routinely recommended.
2.2.3 B-type natriuretic peptide as a prognostic tool among the elderly
Traditional cardiovascular risk factors, such as hypertension, dyslipidaemia, and obesity,
seem to lose their value in predicting mortality for an elderly population and are often
associated with a neutral or even better prognosis (Schupf et al. 2005; Oates et al. 2007;
Takata et al. 2007). Natriuretic peptides are known to predict mortality in a wide variety of
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cardiovascular diseases, including acute and chronic heart failure, myocardial infarction as
well as stable and unstable coronary angina (Vuolteenaho et al. 2005; Daniels et al. 2007)
(Wang et al. 2004). They have also performed well as a risk marker of mortality among the
elderly, whereas CRP, another recently established cardiovascular risk marker for the
general population, has failed to provide the same accuracy as a harbinger of mortality
among aged populations (Wallen et al. 1997; Wallen et al. 1997; Strandberg et al. 2000;
Kistorp et al. 2005).
2.2.3 Cognitive function and B-type natriuretic peptide
BNP has been reported to have an association with cognitive dysfunction in heart failure
patients (Gunstad et al. 2006; Feola et al. 2007). In one study BNP levels were elevated in
patients with subcortical vascular dementia, but not among age-matched controls or
among patients with Alzheimer’s disease (Kondziella et al. 2009). In another study
increased levels of midregional pro-atrial natriuretic peptide, which is equivalent to NT-
ANP as explained earlier, were found in patients with AD when compared to healthy
controls (Buerger et al. 2009). Recently, it was shown that MR-proANP predicted the
progression of mild cognitive impairment to AD in persons below the age of 72 years
(Buerger et al. 2011). In one study with small group of patients with dementia, but no
cardiovascular disease, BNP levels were significantly associated with cognitive function,
whereas levels of ANP were normal (Naito et al. 2009).
2.3 MINI MENTAL STATE EXAMINATION SCORE
2.3.1 Mini Mental State Examination score
The Mini Mental State Examination (MMSE) score is a simple questionnaire originally
developed for screening dementia (Folstein et al. 1975). It includes questions and problems
in a number of areas: the time and place of the test, repeating lists of words, arithmetics,
language use and comprehension, and basic motor skills. The MMSE score has a
maximum of 30 points. An MMSE score of 18 to 23 points has been considered to suggest
mild impairment and a score below 18 moderate to severe impairment of cognitive
function. Individuals with dementia usually score less than 18 points (Bassuk et al. 2000).
The MMSE score has been validated in a Finnish population, and 24 points correspond to
the 5th percentile (Pulliainen et al. 2007).
2.3.2 Prognostic value of Mini Mental Examination score among the elderly
Severe cognitive decline, defined as an MMSE score of less than 18 points, and dementing
illness have a remarkable impact on mortality (Kelman et al. 1994; Fried et al. 1998), but
the role of modest impairment is less clear (Fried et al. 1998; Stump et al. 2001; Nguyen et
al. 2003; Strandberg et al. 2009). Studies using an MMSE score of 18–23 as a definition of
mild cognitive impairment (Bassuk et al. 2000; Strandberg et al. 2009) have found this
criterion  to  be  a  significant  predictor  of  mortality;  the  study  by  Bassuk  et  al.  only  in
individuals aged less than 80 years. A study employing another measure of cognition, the
Short Portable Mental Status Questionnaire, showed no predictive value for mild cognitive
impairment (Stump et al. 2001). Previous studies examining the impact of modest
cognitive impairment on mortality have often relied solely on the MMSE score to exclude
those with different forms of dementing illnesses (Bassuk et al. 2000; Nguyen et al. 2003;
Strandberg et al. 2009). Many participants with undiagnosed dementia and, therefore,
compromised  prognosis  but  who  have  a  relatively  preserved  MMSE  score  have  most
probably been included in those studies.
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2.4 ECHOCARDIOGRAPHY
2.4.1 Mitral inflow pattern
The filling of the left ventricle through the mitral valve in diastole happens in two phases.
The pulsed Doppler technique can be used to measure the mitral inflow pattern. The early
component is entitled the E wave and the late component the A wave. Aging is associated
with left ventricular stiffening and the attenuation of the peak early diastolic filling
velocity (E). Consequently, the atrial systole component of the diastolic filling (A)
increases, the net result being a decrease in the echocardiographically measured E/A ratio
(Dalen et al. 2010). Despite the introduction of tissue Doppler measures, the measurement
of the E/A ratio is an integral part of estimating the diastolic function of the heart (Oh et al.
2006). Inverted mitral inflow (E/A <1.0) is used as a marker of the mildest form of left
ventricle diastolic dysfunction, impaired relaxation with normal filling pressure (Oh et al.
2006). In the elderly, lower E/A limits—0.6 or, more commonly, 0.75—have been used for
an inverted mitral inflow pattern (Bella et al. 2002; Redfield et al. 2003; Kardys et al. 2009).
Among populations of advanced age, the attenuation of the E/A ratio can be caused
by many mechanisms not related to heart failure (Finucci et al. 1996; Bossone et al. 1999;
Salerno et al. 2003; Gurudevan et al. 2007). The elderly often have an impaired ability to
sense thirst (Waldreus et al. 2010), and chronic dehydration is common among the elderly,
especially among cognitively impaired individuals (Morley 2002). Dehydration is known
to co-exist with malignancies (Price). It decreases the filling pressure of the left ventricle,
which attenuates the E wave and, consequently, lowers the mitral E/A ratio. Cognitive
impairment and, in particular, dementive illnesses are known to have a remarkable impact
on prognosis (Kelman et al. 1994; Larson et al. 2004). An inverted mitral inflow pattern is
known  to  be  more  common  among  individuals  with  chronic  lung  disease  or  chronic
pulmonary embolism (Bossone et al. 1999; Gurudevan et al. 2007). Liver failure is also
known to cause intravascular hypovolaemia, and an inverted mitral inflow pattern has
been shown to co-exist with liver cirrhosis (Finucci et al. 1996; Salerno et al. 2003).
2.4.2 Prognostic value of echocardiographic measures in the general population
Several large population-based studies have investigated the prognostic value of
echocardiographic measures for mortality. Left ventricular mass (Levy et al. 1990; Gardin
et al. 2001; Kardys et al. 2009) and ejection fraction (EF) (Fried et al. 1998; Redfield et al.
2003; Wang et al. 2003) have been demonstrated to predict mortality almost uniformly in
several variably aged populations. Only one of the larger studies, remarkably the one with
the shortest follow-up, showed no association with EF and mortality (Kardys et al. 2009).
The diastolic left ventricular mitral inflow pattern recorded with the Doppler method has
been connected to mortality in several studies. A restrictive mitral inflow pattern (E/A >
1.5) and an inverted mitral inflow pattern have also been linked to total and
cardiovascular mortality (Bella et al. 2002; Kardys et al. 2009), with one of the studies
finding the association only in men (Kardys et al. 2009). Diastolic dysfunction defined with
a combination of pulsed Doppler and tissue Doppler techniques has been shown to predict
total mortality in the general population (Redfield et al. 2003).
2.4.3 Left ventricular systolic function and lipids
Therapy with statins has been shown to diminish the occurrence of clinical heart failure in
post-infarct patients (Pedersen et al. 1994; Sola et al. 2006), and it appears to have a
positive effect on cardiac function in patients with non-ischemic cardiomyopathy (Sola et
al. 2006) as well as in post-infarction patients with primary hyperlipidaemia (Talini et al.
2008). Low levels of HDL cholesterol have been shown to associate with decreased systolic
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function in post-infarct patients and angina pectoris patients without obstructive coronary
disease (Wang et al. 1999).
Hyperlipidaemia and low HDL cholesterol are known risk factors for atherosclerosis
and coronary disease, which in turn can predispose to heart failure. In addition, HDL has
potent anti-inflammatory and oxidation preventing properties (Banka 1996; Sviridov et al.
2008). HDL also has an anti-thrombotic and anti-adhesive effect on platelets and is known
to protect endothelial function by stimulating endothelial nitric oxide synthase (Sviridov et
al. 2008). Oxidative stress and endothelial dysfunction have been connected to heart
failure and could partly explain the link between lipids and heart dysfunction (Bergamini
et al. 2009).
The use of statins in heart failure patients could potentially be also harmful. Bacterial
endotoxins (lipopolysaccharides) may be removed from circulation by lipoproteins.
Lowering lipoprotein levels by statin treatment could potentially expose HF patients more
to infection (Rauchhaus et al. 2000). Ubiquinone (coenzyme Q10) is a coenzyme in
mitochondrial respiration in cardiac muscle. Plasma levels of ubiquinone have been
inversely associated to excess mortality in HF patients. Statin treatment is known reduce
the plasma level of ubiquinone (Molyneux et al. 2008). The effect of statin treatment on
heart  failure  patients  has  been  addressed  in  two  large  randomized  prospective  trials,
CORONA (Kjekshus et al. 2007) and GISSI-HF (Tavazzi et al. 2008). Rosuvastin treatment
for  patients  with  symptomatic  systolic  heart  failure  (CORONA)  or  systolic  and  diastolic
heart failure (GISSI-HF) was beneficial in neither of the studies. Based on these findings
statin treatment for HF patients regardless of the ethiology is not recommended. In
patients already on statin therapy with appropriate indication, discontinuation is not
necessary if heart failure is diagnosed (Sadek et al. 2009).
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3 Aims of the study
The impact of cardiovascular risk markers on cognition and mortality is known to alter
with aging. The aim of the study was to evaluate the value of BNP along with established
cardiovascular risk markers as a screening test for left ventricular systolic dysfunction, and
as a predictor of cognitive decline and dementive illness during the follow-up. The
independent prognostic power of BNP and MMSE, as well as echocardiographic measures
in an elderly general population was also of particular interest.
The specific aims of the present study were:
1. To find predictors of attenuated left ventricular ejection fraction and systolic
dysfunction in a population-based study of elderly people. (Study I)
2. To examine the value of echocardiographically measured left ventricular
mass, ejection fraction and mitral inflow pattern in predicting cardiovascular
and non-cardiovascular mortality in an elderly general population. (Study II)
3. To compare BNP with other cardiovascular risk markers for their value to
predict the decline of cognitive function and new cases of dementia in an
elderly general population free of dementia. (Study III)
4. To examine the power of BNP and mild cognitive impairment, defined as
MMSE 18–23, as independent predictors of total and cardiovascular mortality
together with established cardiovascular risk markers in an elderly general
population free of severe cognitive impairment. (Study IV)
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4 Material and methods
4.1 STUDY POPULATION
This study is a part of the larger population-based, multidisciplinary Kuopio 75+ health
study focusing on the clinical epidemiology of diseases, medication, and functional
capacity in elderly persons aged 75 years or older. The target population was a stratified
random sample (n=700) of all residents of the City of Kuopio in Eastern Finland who were
aged 75 years or more on 1 January 1998 (N = 4518). The cohort included 700 participants.
Five persons could not be contacted, 79 refused to take part in the study, and fifteen died
before the examination. The remaining 601 participants formed the study population.
4.2 BASELINE DATA
A trained nurse interviewed the participants at the outpatient clinic of the municipal
hospital about their medical history and use of medicines and recorded the medicines they
were currently taking. If a participant was unable to visit the study site, a nurse and
geriatrician visited the home to perform the interview and examination. Medical records
from the municipal health centre, home nursing service, local hospitals and Kuopio
University Hospital were also available. Baseline clinical and demographic data and the
NYHA class were also recorded. Diabetes was defined as a previous diagnosis of diabetes
or a fasting plasma glucose level of 7.0 mmol/l or more. Data on other cardiovascular
conditions were obtained from medical records. Blood systolic and diastolic pressures
were measured twice, and the average of the measurements was recorded. Depression
was screened using Zung’s self-rating Depression Scale (Zung 1965).
Written informed consent was obtained from the study participants or their relatives
as stipulated in the Declaration of Helsinki. The study was approved by the ethics
committee of the Hospital District of Northern Savo and the Kuopio University Hospital.
4.3 LABORATORY MEASURES AND BRAIN IMAGINING
4.3.1 Standard laboratory measures
Complete blood count, creatinine, lipid profile, HDL-C, triglycerides and fasting blood
glucose  were  measured  once  at  Kuopio  University  Hospital  after  12-hour  fasting.  All
serum total cholesterol assays were analysed in the Kuopio University Hospital laboratory
using standard enzymatic techniques. Creatinine clearance was calculated using
creatinine, age and body weight according to Cockcroft-Gault’s formula (Cockcroft et al.
1976). The estimation of low-density lipoprotein cholesterol was calculated using
Friedewald’s formula (Friedewald et al. 1972).
4.3.2 B-type natriuretic peptide
The  blood  samples  for  the  analysis  of  BNP  were  withdrawn  similarly  with  other  blood
samples into chilled tubes containing 1.5 mg K2-EDTA per mL blood after the patient had
been in a supine position for 30 min at 8 a.m. The whole blood was centrifuged and
plasma immediately frozen and stored at -70°C. BNP was extracted from plasma
(Vuolteenaho et al. 1992). The radioimmunoassay protocol has been described previously
for atrial natriretic peptide (ANP) (Vuolteenaho et al. 1992); the BNP assay was performed
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with the same protocol. The BNP antiserum was raised in a rabbit against a carbodiimide
conjugate of synthetic human BNP-32 (Bachem, Bubendorf, Switzerland) and bovine
thyroglobulin (Sigma, St. Louis, USA) using methods published previously (Vuolteenaho
et al. 1985). The sensitivity of the BNP assay was 0.5 pmol/L plasma. The within and
between-assay coefficients of variation in the assay were <10% and <15%, respectively.
With this method, the following plasma levels (mean ± SD) have been detected in healthy
adults aged 20–55 years: BNP 6.25 ± 2.12 pmol/L.
4.3.3 Computed tomography and magnetic resonance imagining of the brain
Brain imaging either by computed tomography or magnetic resonance imaging was
carried  out  for  all  participants  with  a  suspicion  of  a  dementing  illness  but  no  brain
imaging in the medical history. The images were routinely analysed by a radiologist and
an experienced neurogeriatrician.
4.4 MEASUREMENT OF COGNITIVE FUNCTION AND DIAGNOSING
DEMENTIVE ILLNESSES
The  study  nurse  used  the  Finnish  version  of  MMSE  score  to  screen  for  cognitive
dysfunction. Dementia was diagnosed as AD, VaD, dementia with Lewy bodies, or
dementia due to other medical conditions by an experienced neurogeriatrician according
to the DSM-IV criteria and Consensus guidelines for the clinical and pathological
diagnosis of dementia with Lewy bodies (McKeith et al. 1996). A clinical diagnosis of
dementia was established, and the type of the dementia was determined in consensus
meetings using all data available.
4.5 ECHOCARDIOGRAPHY
M-mode  echocardiography  was  performed  by  a  single  experienced  cardiologist  (R.K.)
with a Hewlett Packard Sonos 1000 ultrasound system (Hewlett- Packard Company,
Andover,  MA,  USA)  using  a  2.5  MHz  transducer.  The  measurements  of  the  left  atrium,
septal wall thickness at end-diastole (SWTd), posterior wall thickness at end-diastole
(PWTd), as well as left ventricular systolic (LVIDs) and diastolic diameter (LVIDd) were
obtained and averaged from three to five cardiac cycles. M-mode measurements were
performed according to the recommendations of the American Society of
Echocardiography (Sahn et al. 1978). Two-dimensional (2D) left ventricular ejection
fraction (EF) measurements in the apical long axis view were estimated by means of a
single-plane ellipse formula (Folland et al. 1979). Left ventricular mass was calculated with
the formula 0.8 x 1.04[(LVIDd + PWTd + SWTd) ³-(LVIDd)³] + 0.6) and indexed to the body
surface area (Devereux et al. 1986). Significant valvular disease was defined as a mean
pressure gradient across the aortic valve of 20 mmHg or more, as a valve regurgitation
class II–IV or as mitral valve area of less than 1.5cm². The mitral inflow pattern was
recorded by setting the pulsed Doppler sample volume at the mitral leaflet tips.
4.6 FOLLOW-UP VISIT AT FIVE YEARS
A total of 303 participants free of dementia at the baseline visit attended the follow-up
visit  at 5 years (Study III).  Of the 161 participants missing, 133 expired during the study
period  and  28  either  refused  to  continue  the  study  or  could  not  be  contacted.  The
collection of baseline data and the diagnostic process for possible dementia, including
MMSE score and brain imagining, were repeated.
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4.7 FOLLOW-UP FOR MORTALITY
Mortality data were obtained from Statistics Finland, which is the national health register
authority in Finland. There were no losses during follow-up. All deaths that occurred
between March 1998 and November 2006 were recorded. Life span was calculated from
the date of examination in 1998 to 30 November 2006. The causes of deaths were classified
according to the Tenth International Classification of Disease (ICD-10), and codes I00–99
were classified as cardiovascular deaths. Other deaths were classified as non-
cardiovascular.
4.8 PATIENT INCLUSION IN SUB-STUDIES
4.8.1 Study I
Echocardiography was performed for 355 randomly selected participants, who formed the
final cohort of this study.
4.8.2 Study II
Echocardiography was performed for 355 randomly selected participants; a mitral inflow
E and A wave could be recorded for 323 individuals who then formed the final cohort of
this study.
4.8.3 Study III
Participants with diagnosed dementia (n=137) were excluded from this sub-study, and the
final study population included 464 attendants. A total of 303 participants attended the
follow-up visit  at  5  years.  Of  the  161  participants  missing,  133  expired during the  study
period and 28 either refused to continue the study or could not be contacted.
4.8.4 Study IV
Participants with 18 MMSE points or more were included (n=499) in this study.
4.9 STATISTICAL ANALYSIS
4.9.1 Ejection fraction, high-density lipoprotein and systolic dysfunction
Comparisons of baseline characteristics between the groups were performed with the aid
of the t test for independent samples or the Mann-Whitney U-test for continuous variables,
based  on  whether  the  distribution  was  Gaussian  (Studies  I,  II  and  IV).  In  Study  III  the
differences between the groups were tested with an ANOVA test for independent samples
for continuous variables. A prior logarithmic transformation was performed for non-
normally distributed variables. The ²-test was used for categorical data.
Binary logistic regression models were applied to determine the impact of various
predefined independent variables on EF as a dichotomous variable (EF or > 45%). One
more logistic regression model was constructed for EF, using all the independent variables
with significant associations in univariable models. Both the highly collinear lipid
parameters total cholesterol and HDL cholesterol showed a significant association in
separate models; however, only the one with the stronger association with EF (i.e., HDL
cholesterol) was used in the final model. Hazard ratios (HR) for continuous variables were
scaled to show the risk as the independent variable changes by one standard deviation
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(SD). The testing scheme covered, separately, the entire study group (n=355) as well as
participants with and (n=85) without (n=270) a previous heart failure diagnosis.
 Linear regression models for the individuals with no prior diagnosis of heart failure
(n=270) were applied to determine the impact of various independent variables on EF as a
continuous variable. First, the standardised regression coefficients (beta) of variables listed
in  Table  2 were determined using separate linear regression models for each of these
parameters. Finally, one more linear regression model was constructed for EF, using all
the variables with significant coefficients in the initial models.
The impact of BNP and HDL cholesterol on EF was assessed with one-way analysis
of variance (ANOVA) for BNP tertile groups, and a t–test for independent samples for the
HDL groups below and at least 1 mmol/l. Sample size analysis was calculated for ANOVA
with three equal-sized groups. If  SD for EF is 0.2 in each group, the largest difference in
mean EF between the groups 0.10, alpha 0.05 and beta 0.8, then roughly 80 patients are
needed for each group.
4.9.2 Echocardiography and mortality
Due to the low number of individuals in group E/A > 1.5, statistical comparisons were
made only between the groups E/A < 0.75 and E/A 0.75–1.5. Age- and sex-adjusted as well
as pre-specified multivariable-adjusted Cox proportional hazards regression models for
mortality were constructed to calculate HRs with 95% confidence intervals (CI) for EF,
both as a continuous and as a dichotomized variable (pre-specified cut-off point 0.35), for
left ventricular mass-index and E/A < 0.75. Analysis was repeated using cardiovascular as
well  as  non-cardiovascular  mortality  as  end-points.  The  age-  and  sex-adjusted  Cox
proportional hazards models for E/A < 0.75 vs. E/A 0.75–1.5, and for EF < 0.35 vs. EF  0.35,
were  used  to  construct  cumulative  survival  curves  for  total,  cardiovascular  and  non-
cardiovascular mortality.
4.9.3 B-type natriuretic peptide and cognitive dysfunction
MMSE score at baseline and the change in MMSE score between the two visits (1998 and
2003) were studied as continuous variables. Univariable linear regression analysis was
used to determine the impact of various baseline variables on the initial MMSE score and
on the  change in  MMSE score  over  the  study period (Table  6).  Binary logistic  regression
models were applied to determine the impact of each baseline variable on the onset of
dementia during the follow-up (Table 6). One more logistic regression model was
constructed for new dementia cases using all the independent variables with a significant
association in the univariable models. A separate regression model was adjusted to
baseline MMSE score to determine the value of the variables for the prediction of dementia
independent of MMSE score.
The baseline BNP levels of the participants are illustrated using box plots according
to their status of dementive illness after the follow-up (Figure 3), with the differences
between the groups assessed with ANOVA.
4.9.4 B-type natriuretic peptide, Mini Mental State Examination score and mortality
We used a Cox proportional hazards model with penalised splines (Greenland 1995)
adjusted for age and sex to examine whether the association between mortality and the
independent variables BNP and MMSE score changes in a nonlinear fashion across the full
range of these independent parameters. A priori, we selected three degrees of freedom
based on biological plausibility. Nonlinear models did not differ from linear models with
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statistical significance using an analysis of deviance table with the ²-test, and for the rest
of the tests, we applied linear models.
Cox proportional hazards regression models for total and cardiovascular mortality
were constructed to calculate HR with 95% CI for BNP, the MMSE score, and the variables
listed in Table 7. The proportionality assumption was checked for the main analyses based
on correlations of survival rankings with Schoenfeld residuals; all covariates fulfilled this
criterion. BNP and MMSE score were tested both as continuous and categorical variables
(Table 8). Regarding the cut-off points for categorical formulations, we used the pre-
specified <24 points for MMSE score, which was approximately the 20th percentile.
Similarly, the 80th percentile for BNP (79.7 pg/ml) was used as a cut-off point to facilitate
comparisons with earlier BNP studies (Bassuk et al. 2000; Strandberg et al. 2009).
Cardiovascular risk markers and previous illnesses with a significant or near-significant (p
<.100) stratifier capacity for mortality and cardiovascular mortality, separately, were used
as covariates in multivariable Cox proportional hazards models. The analyses were
repeated in pre-specified subgroups: participants with no diagnosed dementia (n=454) and
participants with no previously diagnosed heart failure (n=376). HDL cholesterol and total
cholesterol were highly collinear and both associated with mortality, but only the one with
the stronger association, namely HDL cholesterol, was used in the Cox proportional
hazards models.
4.9.5 Proportionality assumption, level of significance and statistical software
The proportionality assumption was checked for the main analyses based on correlations
of survival rankings with Schoenfeld residuals; all covariates fulfilled this criterion. All
tests were 2-sided, and p <.05 was considered significant. The data was analysed with
SPSS release 15.0 for Windows (SPSS Inc. Chicago, Illinois).
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5 Results
5.1 PREDICTORS OF ATTENUATED EJECTION FRACTION
The predictive power of clinical variables on ejection fraction was tested in a subgroup as
described in 4.8.1. Baseline data were analysed for the whole study population, and for
subgroups with and without previously diagnosed heart failure separately. Participants
with heart failure were older, and their use of cardiovascular medications and history of
other cardiovascular diseases were more common. BNP levels were also higher among the
heart failure group (Table 1).
5.1.1 Predictors of attenuated ejection fraction among participants with no history of
heart failure
The variables tested independently for their impact on EF as a dichotomous variable are
listed in Table 2.  Age, HDL cholesterol and the use of an ACE inhibitor or an ARB were
significantly connected to EF. Remarkably, BNP, creatinine clearance, sex, the use of a
beta-blocker  and  previous  myocardial  infarct  were  not  linked  to  EF.  In  the  final  logistic
regression analysis, HDL cholesterol (HR=1.52; p=0.013) and age (HR=0.63; p=0.002) were
the only variables to have an significant association with EF.
EF was also studied as a continuous variable. Variables in Table 2 were
independently tested in linear regression analysis for their relation to EF in the group with
no existing heart failure diagnosis (n=270). HDL cholesterol (beta = 0.123; p=0.04) and age
(beta= -0.147; p=0.02) were the only variables to have an impact on EF. In the multivariable
linear  regression  analysis,  they  were  both  independently  associated  with  EF  (HDL
cholesterol, beta=0.127, p=0.04; and age, beta=-0.150, p=0.01).
5.1.2 Predictors of attenuated ejection fraction in the whole study population and
among participants with a history of heart failure
HDL cholesterol as a continuous variable was associated with ejection fraction of less than
0.45 (HR=1.53; p=0.002) in the whole study population, but not among the heart failure
patients. However, HDL cholesterol as a dichotomous variable (HDL cholesterol  or >
1mmo/l) also showed a significant association in the latter group (HR=1.70; p=0.02).
HDL cholesterol was the only parameter to be significantly connected (beta = 0.109;
p=0.04) to EF as a continuous variable in the whole study group, whereas for heart failure
patients none of the parameters yielded a significant association.
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Table 1. Characteristics  of  the  participants  with  an  echocardiographic  examination.  Data  is
provided  for  the  whole  study  population  and  according  to  the  history  of  heart  failure,
separately (Study 1).
All No heart failure Heart failure
p-
value
(n=355) (n=270) (n=85)
Age in years, mean (SD) 80.3 (4.5) 79.6 (4.2) 82.7 (4.8) <0.001
Women, % 72.7 72.6 72.9 NS
BMI, mean (SD) 26.3 (4.5) 25.9 (4.1) 27.7 (5.5) 0.002
Medication
Regular medication, % 90.7 88.1 98.8 0.003
Beta-blocker, % 39.7 35.6 52.9 0.004
ACE-i/ARB, % 19.7 11.5 45.9 <0.001
Diuretics, % 36.1 23.3 76.5 <0.001
Ca-channel blockers, % 15.5 16.3 12.9 NS
Long-acting nitrates, % 29.3 20.4 57.6 <0.001
Statins, % 3.9 3.3 5.9 NS
Previous illnesses
Previous MI, % 32.1 27.8 45.9 0.002
Hypertension, % 57.7 59.3 52.9 0.008
Heart failure, % 23.9 - 100
Symptomatic ASO, % 10.1 8.1 16.5 0.027
Diabetes, % 20.6 16.3 34.1 <0.001
Previous stroke, % 13 10.7 20 NS
Smoking
Non-smoker, % 75 74.1 77.8 NS
Ex-smoker, % 20.6 20.9 19.8 NS
Smoker, % 4.4 4.9 2.5 NS
Laboratory data
Haemoglobin, mean (SD) g/l 133.9 (12.8) 133 (12.9) 134 (12.7) NS
Cr-Cl, mean (SD) ml/min 51.5 (15.9) 52.7 (14.5 47.2 (19.7) 0.008
BNP, mean (SD) pg/ml 53.5 (59.2) 45.4 (44.5) 79.4 (87.0) <0.001
Cholesterol, mean (SD) mmol/l 5.67 (1.18) 5.75 (1.15) 5.4 (1.2) 0.016
LDL cholesterol, mean (SD) mmol/l 3.53 (1.0) 3.59 (1.0) 3.30 (1.0) 0.034
HDL cholesterol, mean (SD) mmol/l 1.46 (0.41) 1.51 (0.4) 1.3 (0.39) <0.001
Triglycerides, mean (SD) mmol/l 1.51 (0.80) 1.45 (0.75) 1.70 (0.90) 0.009
Echocardiographic parameters
Ejection fraction, mean (SD) 0.54 (0.13) 0.55 (0.12) 0.52 (0.20) NS
Systolic dysfunction EF 0.45, % 23.4 21.5 29.4 NS
LVMI, mean (SD), g/BSA m² 96.1 (34.6) 94.3 (35.2) 102 (32.0) NS
Left ventricular hypertrophy, % 37.4 36.1 42.4 NS
Significant valvular heart disease, % 22.8 19.6 32.9 0.011
Left ventricular hypertrophy was defined as a left ventricular mass index  > 95 g /m² for women and > 115 g/m² for men; significant
valvular disease was defined as a mean pressure gradient across the aortic valve > 20 mmHg, valve regurgitation class II–IV, or
mitral valve area < 1.5 cm².
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5.1.3 Association of B-type natriuretic peptide and high-density lipoprotein cholesterol
with other echocardiographic findings
The presence of significant valvular disease and left ventricular hypertrophy were tested
as dichotomous variables in the total study population. BNP was clearly associated with
significant valvular disease (HR=1.557; p<0.0001), but not with left ventricular
hypertrophy (HR=1.093; p=0.262), whereas HDL cholesterol did not show any association
with either of the variables. In order to exclude the possible effect of statin treatment, the
analyses concerning HDL cholesterol were repeated without statin users (n=14). This did
not produce any significant changes in results (data not shown).
Table 2. Binary logistic regression analysis presenting odds ratios and their significance of
clinical  variables  for  their  association  with  ejection  fraction  as  a  dichotomous  ( or  >
0.45) variable; and, similarly, linear regression analysis, standardised regression
coefficient (beta) and their significance, with ejection fraction as a continuous variable
(Study I)
EF  or > 0.45 EF
HR p-value beta p-value
Age   0.65 0.002 -0.147 0.015
Sex 0.65 0.175 -0.102 0.095
BMI   1.17 0.302 -0.038 0.538
Smoking 0.25 0.679 -0.06 0.334
NYHA class 0.51 0.126 -0.044 0.498
Diabetes 1.28 0.561 0.009 0.887
Hypertension 1.12 0.683 0.025 0.686
Previous MI 1.43 0.305 0.062 0.311
Symptomatic ASO 0.92 0.882 0.011 0.856
Previous stroke 0.67 0.245 -0.114 0.061
Heart rate 1.24 0.306 -0.04 0.511
Haemoglobin 0.88 0.95 -0.001 0.984
Creatinine clearance 1.31 0.13 -0.028 0.646
Cholesterol 1.43 0.025 0.093 0.126
LDL cholesterol 1.24 0.16 0.059 0.338
HDL cholesterol 1.51 0.013 0.123 0.043
Triglycerides 1.07 0.584 -0.001 0.985
BNP 1.09 0.594 0.022 0.718
Systolic BP 1.35 0.056 0.092 0.133
Diastolic BP 0.84 0.786 0.038 0.542
ACE-i/ARB 0.23 0.046 0.114 0.06
Other cardiovascular drugs >0.200 >0.200
5.2 MORTALITY PREDICTING POWER OF ECHOCARDIORAPHIC
PARAMETERS IN AN ELDERLY POPULATION
The associations of echocardiographic measures with total, cardiovascular and non-
cardiovascular mortality were studied in a subgroup of the participants as described in
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Table 3. Baseline characteristics of the participants presented according to their mitral inflow E
per A ratio (Study II)
        E/A
<0.75 0.75-1.50 >1.50 p-value
Characteristics n=151 n=155 n=17
Age in years, mean (SD) 80.1(4.4) 80.1(4.4) 81.2(4.9) 0.910
Women, (%) 75.5 76.8 58.8 0.893
RR, systolic, mean (SD), mmHg 152.0(23.7) 153.4(23.2) 146.7(28.6) 0.588
RR, diastolic, mean (SD), mmHg 77.9(10.5) 75.8(10.8) 74.4(11.8) 0.089
Heart rate, mean (SD), beats/min 67.1(10.2) 67.9(14.0) 68.4(17.3) 0.818
NYHA class, mean (SD) 1.86(0.74) 1.87(0.74) 1.71(0.91) 0.902
BMI, mean (SD) 26.8(4.97) 26.4(4.45) 25.1(3.99) 0.497
MMSE score, mean (SD) 23.0(7.6) 23.7(7.0) 25.7(4.1) 0.449
Echocardiographic measures
EF,  mean (SD) 0.53(0.13) 0.56(0.11) 0.52(0.17) 0.012
LV mass index, mean (SD), g /BSA m² 125.3(47.4) 121.1(50.8) 130.1(57.6) 0.497
LVIDd, mean  (SD), cm 4.74(0.87) 4.71(0.97) 4.84(0.82) 0.841
LAD/BSA, mean (SD), cm 2.20(0.38) 2.30(3.57) 2.61(0.37) 0.018
Valvular heart disease, % 13.2 23.9 41.2 0.019
E/A, mean (SD) 0.62(0.078) 0.94(0.15) 2.05(0.47)
Laboratory parameters
Haemoglobin, mean (SD), g/l 134.6(13.1) 132.2(12.4) 133.5(13.6) 0.096
Creatinine clearance, mean (SD), ml/min 52.6(16.6) 52.3(15.3) 48.9(15.4) 0.904
Cholesterol, mean (SD), mmol/l 5.75(1.20) 5.82(1.16) 5.48(1.27) 0.626
HDL cholesterol, mean (SD), mmol/l 1.43(0.38) 1.53(0.43) 1.41(0.39) 0.018
BNP, mean (SD), pg/ml 35.0(36.7) 54.2(57.4) 67.4(42.0) 0.001
Medication
Beta-blocker, % 33.8 45.2 47.1 0.047
ACE-i/ARBs, % 13.2 18.1 29.4 0.273
Diuretics, % 38.4 29 23.5 0.091
Ca-channel blockers, % 13.9 14.2 17.6 1.000
Statins, % 4 5.8 0 0.598
Previous illnesses
Previous MI, % 33.1 31.6 32.2 0.808
Hypertension, % 55 58.1 58.8 0.483
Heart failure, % 21.2 18.7 17.6 0.344
Diabetes, % 21.2 15.5 23.5 0.237
Previous stroke, % 13.2 11 17.6 0.332
Dementive illness, % 25.2 14.2 5.9 0.011
Comparisons between the groups were performed with the aid of the t test for independent samples or the Mann -
Whitney U-test for continuous variables, based on whether the distribution was Gaussian. The ²-test was used for
categorical data.
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detail in 4.8.2. During a median follow-up period of 8.4 years (interquartile range, [IQR]
8.2–8.6) for survivors and 7.6 years (3.7–8.4) for the whole study population, 177 (54.8%)
participants expired, producing an annual mortality rate of 9.0%. The cause of death was
cardiovascular in 82 (46.3%) cases – malignancy with 26 (14.7%), infection with 15 (8.5%)
and dementia-related reasons with 35 (19.8%) deaths being the other common causes. Due
to the small number of participants with an E/A ratio of > 1.5 (n=17), comparisons were
made between the individuals with E/A < 0.75 and E/A  0.75 – 1.5. Participants with an E/A
ratio of <0.75 as compared to those with an E/A ratio of 0.75–1.5 had a lower ejection
fraction, and significant valve disease was less common. BNP and HDL cholesterol were
significantly lower, and there was a trend towards a higher frequency of the use of
diuretics. There were no differences in previous illnesses between the groups apart from
dementive  illnesses,  which were  more common among participants  with  an E/A ratio  of
<0.75 (Table 3).
5.2.1 Left ventricular mass and mortality
The left ventricular mass index predicted total and cardiovascular mortality in all the
models applied (Table 4). It had no connection to non-cardiovascular mortality.
5.2.2 Ejection fraction and mortality
EF as a continuous variable showed no association with total, cardiovascular or non-
cardiovascular mortality. There was a trend towards higher total, cardiovascular and non-
cardiovascular mortality if EF was dichotomised at 0.35 (Table 4).
5.2.3 Inverted mitral inflow pattern and mortality
An E/A ratio of < 0.75 was associated with total mortality in age- and sex-adjusted as well
as the fully adjusted multivariable model. E/A < 0.75 showed no predictive value in similar
models with cardiovascular mortality in either model, but it was a strong predictor of non-
cardiovascular mortality in both the age- and sex-adjusted as well as the multivariable
model (Table 4).
Table 4. Hazards  ratios  (HR),  95%  confidence  intervals  (95%  CI)  and  p-values  for  total,
cardiovascular  and  non-cardiovascular  mortality  during  a  median  follow  up  of  7.6  years
according to baseline echocardiography measures (Study II)
Cardiovascular Non-cardiovascular
Total mortality mortality mortality
Age and sex-
adjusted HR (95% CI) p-value HR (95% CI) p-value HR (95% CI)
p-
value
E/A < 0.75 1.54 (1.14-2.07) 0.004 1.24(0.80-1.91) 0.336 1.86(1.24-2.80) 0.003
EF 0.89(0.78-1.03) 0.132 0.91(0.75-1.11) 0.335 0.88(0.72-1.08) 0.232
EF <0.35 1.52(0.96-2.41) 0.073 1.66(0.90-3.06) 0.103 1.38(0.69-2.77) 0.366
LV mass index 1.22(1.05-1.34) 0.010 1.35(1.16-1.64) < 0.001 1.00(0.82-1.28) 0.928
Multivariable
adjusted
E/A < 0.75 1.55(1.10-2.19) 0.013 1.31(0.78-2.22) 0.304 1.81(1.13-2.89) 0.013
EF 0.91(0.78-1.07) 0.266 0.95(0.76-19) 0.676 0.87(0.70-1.09) 0.239
EF <0.35 1.37(0.77-2.41) 0.282 1.40(0.64-3.02) 0.355 1.43(0.61-3.33) 0.408
LV mass index 1.22(1.05-1.42) 0.012 1.42(1.16-1.73) < 0.001 1.00(0.78-1.35) 0.879
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5.3 B-TYPE NATRIURETIC PEPTIDE AND COGNITIVE FUNCTION
The association of BNP with cognitive dysfunction and the incidence of dementia during
follow-up was examined in a subgroup of participants as described in 4.8.3. Baseline data
according to BNP tertiles is presented in Table 5. The participants with a higher level of
BNP were more likely to be older and have a history of heart failure, atrial fibrillation or
stroke than those  with a  lower  level  of  BNP.  Systolic  and diastolic  blood pressures  were
lower among the participants with high BNP.
5.3.1 Association of clinical correlates with baseline cognitive function
Lower baseline MMSE score was connected to previously diagnosed heart failure and
stroke as well as higher NYHA class, higher resting heart rate, lower creatinine clearance,
lower HDL cholesterol and higher BNP. In addition, the MMSE score at baseline was
associated with age and the duration of education. No significant association was found
between baseline MMSE score and total cholesterol, smoking, diagnosis of hypertension,
sex, diabetes, BMI, or systolic or diastolic blood pressure (Table 6).
5.3.2 Predictors of decline in Mini Mental State Examination score
The change in MMSE score during the follow-up of five years was, on average, -1.43 (SD
4.95) points. BNP was the only variable to have an impact on the decline in MMSE score
during the follow-up. When adjusted to the level of baseline MMSE score, BNP continued
to predict the decline in MMSE score. The traditional risk factors for cognitive decline,
such as age, education, smoking, baseline MMSE score or cardiovascular risk markers or
illnesses, showed no association with a declining MMSE score (Table 6).
5.3.3 Predictors of newly diagnosed dementias during the follow-up
During the follow-up visit, 59 new cases of dementia were detected. Using univariable
logistic regression, the variables predicting the incidence of dementia during the follow-up
were  age,  a  diagnosis  of  hypertension,  baseline  MMSE  score  and  BNP  (Table  6).  A
multivariable regression model was developed for the above-mentioned significant
variables. The duration of education, hypertension and BNP were independent predictors
of new cases of dementia, while age lost its significance in the multivariable model. The
multivariable model was additionally adjusted to the baseline MMSE score (Table 7).
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Table 5. Baseline  characteristics  and  drug  treatment  in  all  participants  attending  the  5-year
follow-up visit according to their B-type natriuretic peptide tertiles.  (Study III)
BNP pmol/L
Characteristics <23.5 23.5-53.7 >53.7 p-value
Age in years, mean (SD) 78.6 (3.4) 79.8 (4.2) 81.3 (4.6) <.001
Women, % 71.9 70.8 74.2 NS
BMI, mean (SD) 27.3 (4.3) 26.4 (4.5) 25.7 (4.0) 0.007
MMSE, median (IQR) 27 (25-29) 28 (25-29) 26 (24-29) NS
MMSE <24 points, % 13.7 18.2 23.2 0.014
Education in years, mean (SD) 6.8 7.1 7.1 NS
Zung's depression scale, mean (SD) 38.8 (8.6) 39.1 (7.3) 40.2 (8.0) NS
Medication
Regular medication, % 84.3 88.3 96.7 0.001
Beta-blocker, % 28.1 40.9 64.9 <.001
ACE-i/ARBs, % 15 17.5 29.8 0.003
Diuretics, % 34 24 47.7 <.001
Ca-channel blockers, % 19 20.1 14.6 NS
Statins, % 3.9 7.1 3.3 NS
Oral diabetes medication, % 5.9 7.1 9.3 NS
Insulin, % 3.3 3.9 4.0 NS
Previous illnesses
MI, % 26.8 35.7 34.4 NS
Hypertension, % 58.2 63.6 62.3 NS
Heart failure, % 14.4 16.2 43.0 <.001
Atrial fibrillation, % 3.9 10.4 31.1 <.001
Diabetes, % 21.6 15.6 24.5 NS
Stroke, % 6.5 7.1 17.2 0.014
Smoking
Non-smoker, % 69.9 74.0 77.5 NS
Ex-smoker/Smoker, % 30.1 26.0 22.5 NS
Systolic RR, mean (SD), mmHg 151.9 (22.8) 157.1 (24.3) 149.9 (25.0) 0.026
Diastolic RR, mean (SD), mmHg 78.5 (9.54) 77.6 (10.2) 73.7 (11.8) 0.037
Laboratory data
Haemoglobin, mean (SD), g/l 135. 2 (12.6) 133.6 (11.8) 131.7 (13.5) NS
Cr-Cl, mean (SD), ml/min 56.4 (15.1) 54.8 (16.3) 47.2 (13.3) <.001
fP-gluc, mean (SD), mmol/l 5.7 (1.34) 5.5 (1.13) 5.7 (1.52) NS
Lipids
Cholesterol, mean (SD), mmol/l 5.9 (1.21) 5.73 (1.18) 5.45 (1.21) 0.005
LDL cholesterol,  mean (SD), mmol/l 4.08 (1.06) 3.89 (1.02) 3.74 (1.02) NS
HDL choletesterol, mean (SD), mmol/l 1.46 (0.4) 1.56 (0.40) 1.41 (0.43) 0.009
Trigly, median (IQR), mmol/l 1.47 (1.0-2.0) 1.25 (0.9-1.6) 1.29 (1.0-1.8) 0.038
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Table 6. Associations of clinical variables with baseline MMSE, decline in MMSE and new cases
of dementia in five-year follow-up (Study III)
   Baseline
MMSE Decline of MMSE New Dementia Cases
beta p value beta p value HR (95% CI) p value
Age -0.335 <.001 0.056 0.348 1.51 (1.14-2.11) 0.006
Sex 0.077 0.100 0.035 0.562 0.82 (0.42-1.58) 0.547
BMI -0.018 0.696 -0.011 0.861 0.96 (0.72-1.30) 0.748
Education in years 0.392 <.001 0.006 0.921 0.48 (0.32-0.75) <.001
Smoking 0.088 0.060 -0.009 0.878 2.07 (0.96-4.44) 0.062
NYHA class I-II vs. III-IV -0.177 <.001 0.040 0.506 0.95 (0.46-1.96) 0.883
Hypertension 0.032 0.490 -0.049 0.415 0.50 (0.28-0.89) 0.019
Previous heart failure -0.141 0.002 -0.012 0.847 1.25 (0.62-2.51) 0.528
Atrial fibrillation -0.081 0.083 0.115 0.053 1.96 (0.90-4.24) 0.089
Diabetes 0.020 0.664 0.025 0.672 0.49 (0.21-1.13) 0.094
Previous stroke -0.149 0.001 0.036 0.549 1.01 (0.41-2.51) 0.982
Heart rate -0.127 0.006 -0.107 0.071 0.87 (0.58-1.14) 0.237
Haemoglobin 0.125 0.007 -0.071 0.234 0.77 (0.60-1.13) 0.137
Creatinine clearance 0.182 <.001 -0.075 0.207 0.73 (0.53-1.00) 0.071
Cholesterol 0.067 0.151 0.070 0.242 1.13 (0.84-1.52) 0.411
LDL cholesterol 0.02 0.664 0.082 0.171 1.16 (0.87-1.54) 0.322
HDL cholesterol 0.174 <.001 -0.015 0.802 0.96 (0.72-1.29) 0.798
Triglycerides -0.079 0.091 0.036 0.551 1.06 (0.78-1.44) 0.710
BNP -0.151 0.001 0.140 0.019 1.55 (1.13-2.12) 0.007
Systolic BP 0.060 0.197 -0.056 0.348 1.00 (0.61-1.27) 0.499
Diastolic BP 0.085 0.070 -0.062 0.297 0.80 (0.58-1.00) 0.071
Baseline MMSE - - 0.007 0.906  0.34 (0.23-0.89) <.001
Table 7. Multivariable logistic regression model presenting adjusted odds ratios (OR) and 95%
confidence  intervals  (CI)  per  1  standard  deviation  increase  in  clinical  variables  for  the
association with future dementia. The model on the left includes the variables significant in
Table 6. The model on the right is similar but also adjusted with the baseline MMSE.
OR (95% CI) p-value
MMSE adjusted OR
(95% CI) p-value
Age 1.30 (0.89-1.88) 0.172 1.28 (0.73-1.60) 0.18
Hypertension 0.53 (0.27-0.95) 0.034 0.52 (0.27-1.00) 0.05
Education in years 0.50 (0.33-0.77) 0.001 0.69 (0.44-1.07) 0.10
BNP 1.53 (1.09-2.16) 0.016 1.46 (1.03-2.09) 0.03
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Testing  was  further  extended  to  subgroups  of  participants  with  no  previously
diagnosed heart failure (n=346) and no stroke history (n=413). In a subgroup with no
previous heart failure, BNP was significantly associated with new dementia cases when
tested both alone (HR=1.49; 95% CI, 1.07-2.09; p=.020) and in a multivariable model with
age, the duration of education and diagnosed hypertension (HR=1.51, 95% CI, 1.05-2.18;
p=.026).  In  a  subgroup  free  of  stroke,  BNP  remained  a  significant  predictor  of  future
dementia with no material change in the results (data not shown).
Dementias were further classified as AD (n=42), Vad (n=10), dementia with Lewy
bodies (n=3) and other dementias (n=4). The BNP levels of the participants with no
dementia, AD and VaD at follow-up are presented using a box-plot in Figure 3. When
studied separately according to the type of dementia, baseline BNP was predictive of both
AD (HR, 1.59; 95% CI, 1.09-2.30; p= .015) and VaD (HR, 2.71; 95% CI, 1.31-5.60; p= .007)
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Figure 3. Mean±standard deviation B-type natriuretic peptide (BNP) of the participants.
Participants divided into groups according to their follow-up visit dementia status. Participants
with no dementia (N=230) BNP=39.3±37.2 pg/ml, Alzheimer’s disease (N=42)
BNP=56.9±57.6 pg/ml, Vascular dementia (N=10) BNP=79.6±56.7 pg/ml. ANOVA p= .001 in
between the groups (Study III).
No dementia Alzheimer’s
disease
Vascular
dementia
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5.4 B-TYPE NATRIURETIC PEPTIDE AND MINI MENTAL STATE
EXAMINATION SCORE AS PREDICTORS OF MORTALITY
Predicting  the  power  of  clinical  variables  on  total  and  cardiovascular  mortality  with  the
special emphasis on BNP and MMSE score was studied in a subgroup of the participants
as described in detail in 4.8.4. Participants were divided according to their survival status
for the analysis of baseline characteristics. During a median follow-up period of 8.4 years
(8.2–8.6) for survivors and 7.9 years (2.7–8.4) for the whole study population, 258 (51.7%)
participants expired, producing an annual mortality rate of 8.3%. The cause of death was
cardiovascular in 139 (53.9%) cases – malignancy with 44 (17.1%) and infection with 22
(8.5%) deaths being the other common causes.
Compared  with  survivors,  the  non-survivors  were  older  and  more  likely  to  have  a
history of heart failure, atrial fibrillation, or stroke. (Table 8). In a comparison, BNP was
48.6 pmol/L (24.0–86.5) for non-survivors vs. 27.2 pmol/L (16.2–47.9) for survivors (p<
.001). The MMSE score among the non-survivors was 26 (24–29) and among survivors 28
(25–29) (p< .001).
5.4.1 Predictors of total mortality
MMSE score and BNP as continuous and dichotomous variables were significantly linked
to mortality when tested alone or in a sex and age-adjusted model. The age- and sex-
adjusted mortality risk increased with the increase in the quintile of BNP and MMSE score.
The HR between the lowest and highest quintile for BNP was 2.75, and for MMSE the HR
was 2.01. Sex and age-adjusted survival curves and their significance are presented in
Figure 4.
In a fully adjusted multivariable model with multiple predefined clinical correlates as
co-variables, BNP was a clear and MMSE score a borderline prognostic predictor of
mortality.  The  HRs  and  their  significance  are  presented  in  Table  9.  Concerning  other
significant predictors in the model, age (HR=1.71; 95% confidence interval [CI]=1.42–2.11;
p< .001), systolic blood pressure (HR=0.80; 95% CI=0.68–0.98; p= .029), diabetes (HR=1.65;
95% CI=1.14–2.38; p= .008), continuous MMSE score (HR= 0.81; 95% CI=0.70–0.94; p= .007),
and continuous BNP (HR=1.44; 95% CI=1.22–1.77; p< .001) were independently associated
with  mortality.  Regarding  cardiovascular  morbidities,  only  a  history  of  stroke  showed  a
trend towards greater mortality (HR=1.53; 95% CI=0.98–2.36, p=.07). A history of heart
failure, myocardial infarction or atrial fibrillation was not independently associated with
total mortality (p> .100 for all).
5.4.2 Predictors of cardiovascular mortality
MMSE score and BNP as continuous and dichotomous variables were significantly linked
to mortality when tested alone or in a sex- and age-adjusted model. The age- and sex-
adjusted mortality risk increased significantly with the increase in the quintile of BNP. HR
between the  lowest and highest quintile for BNP was 3.29. A similar model for the MMSE
score  showed  only  a  trend  towards  higher  mortality  among  the  participants  with  the
higher MMSE score (HR 1.49). Age- and sex-adjusted survival curves and their
significance are presented in Figure 4.
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Table 8. Baseline characteristics of the participants with an MMSE >17 points by their survival
status (Study IV)
Survivors
(n=258)
Nonsurvivors
(n=241) p-value
Age in years , mean (SD) 78.5 (3.4) 81.4 (4.5) <.001
Women, n (%) 182 (75.2) 179 (69.4) 0.126
BMI, mean (SD) 27 (4.2) 25.8 (4.7) 0.005
Smoking, n (%) 57 (23.7) 73 (28.4) 0.227
NYHA class III or IV (%) 45 (19) 73 (30.7) 0.003
MMSE score, median (IQR) 28 (25-29) 25 (23-28) <.001
MMSE score <24 points, n (%) 31 (12.9) 85 (32.9) <.001
Dementia at examination, n (%) 8 (3.3) 37 (14.3) <.001
Education in years, mean (SD) 6.9 (3.4) 6.8 (3.5) 0.798
Zung's self-rating depression scale, mean  (SD) 38.2 (7.7) 40.7 (8.0) 0.001
Medication
Regular medication, n (%) 209 (86.7) 239 (92.6) 0.029
Beta-blocker, n (%) 105 (43.6) 113 (43.8) 0.959
ACE-i/ARB, n (%) 45 (18.7) 57 (22.1) 0.344
Diuretics, n (%) 65 (27.0) 112 (43.4) <.001
Ca-channel blockers, n (%) 42 (17.4) 44 (17.1) 0.912
Statins, n (%) 20 (8.3) 3.0 (1.2) <.001
Previous illnesses
Previous MI, n (%) 70 (29.0) 95 (36.8) 0.065
Hypertension, n (%) 157 (65.1) 143 (55.4) 0.084
Heart failure, n (%) 39 (16.2) 84 (28.6) <.001
Atrial fibrillation, n (%) 28 (11.6) 48 (18.6) 0.03
Diabetes, n (%) 41 (17.0) 62 (24.0) 0.053
Previous stroke, n (%) 11 (4.6) 38 (14.7) .<001
Heart rate per minute, mean (SD) 68.4 (13.7) 68.7 (13.2) 0.834
Systolic BP, mean (SD), mmHg 157.2 (23.7) 147.7 (23.9) <.001
Diastolic BP, mean (SD), mmHg 78.2 (10.0 74.7 (11.4) <.001
Laboratory data
Haemoglobin, mean (SD), g/l 134.9 (11.7) 131.8 (13.6) 0.006
BNP, median (IQR), pmol/L 27.3 (16.2-47.9) 48.6 (24.0-86.5) <.001
Creatinine clearance, mean (SD), ml/min 55.3 (14.7) 49.4 (15.6) <.001
fP-glucose, mean (SD), mmol/l 5.5 (1.2) 5.7 (1.4) 0.352
Lipids
Cholesterol, mean (SD), mmol/l 5.9 (1.08) 5.5 (1.17) 0.001
LDL cholesterol,  mean (SD), mmol/l 4.0 (0.98) 3.8 (1.12) 0.0019
HDL cholesterol, mean (SD) mmol/l 1.55 (0.40) 1.40 (0.41) <.001
Triglycerides, median (IQR), mmol/l 1.32 (0.95-1.30) 1.32 (0.97-1.78) 0.738
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The  independent  predictors  of  cardiovascular  mortality  in  a  multivariable  Cox  model
were age (HR=1.71; 95% CI=1.42–2.75; p< .001), systolic blood pressure (HR=0.74; 95%
CI=0.58–0.95; p= .016), NYHA class III–IV vs. I–II (HR=1.64; 95% CI=1.02–2.64; p= .044),
diabetes (HR=1.71; 95% CI= 1.05–2.80; p= .033), and BNP (HR= 1.72; 95% CI=1.37–2.15; p<
.001). None of the cardiovascular conditions with an association to mortality (P< .100) were
independent predictors of cardiovascular mortality when tested in the multivariable
model (P>.100 for all).
Importantly, the MMSE score showed no association with cardiovascular mortality
either as a continuous variable or in a dichotomous formulation when the known risk-
factors were fitted into the same model (Table 9). Removing BNP from the model did not
materially change the result for MMSE score.
Table 9. Hazard ratios (HR) for total and cardiovascular mortality during a median mollow-up
of 7.9 years according to baseline BNP and MMSE score (Study IV)
Total mortality
HR (95% CI) per
1-SD increase in
log variable
p-
value
HR (95% CI) for values
above the 80th percentile
for †BNP and below the
20th percentile for
‡MMSE score
p-
value
BNP
Unadjusted model 1.64 (1.44-1.87) <.001 2.63 (2.00-3.44) <.001
Age- and sex-adjusted model 1.47 (1.30-4.06) <.001 2.17 (1.65-2.86) <.001
Multivariable model # 1.44 (1.22-1.70) <.001 1.85 (1.28-2.66) 0.001
MMSE score
Unadjusted model 0.65 (0.58-0.73) <.001 2.32 (1.79-3.01) <.001
Age- and sex-adjusted model 0.74 (0.65-0.84) <.001 1.82 (1.38-2.41) <.001
Multivariable model # 0.81 (0.70-0.94) 0.007 1.40 (1.00-1.97) 0.048
Cardiovascular mortality
BNP
Unadjusted model 1.84 (1.56-2.18) <.001 3.01 (2.11-4.29) <.001
Age- and sex-adjusted model 1.65 (1.38-1.97) <.001 2.40 (1.65-3.43) <.001
Multivariable model # 1.72 (1.37-2.15) <.001 2.18 (1.32-3.56) 0.002
MMSE score
Unadjusted model 0.68 (0.58-0.79) <.001 2.21 (1.55-3.17) <.001
Age- and sex-adjusted model 0.81 (0.68-0.96) 0.017 1.62 (1.1-2.38) 0.013
Multivariable model # 0.92 (0.75-1.14) 0.437 1.11 (0.70-1.76) 0.659
†Hazard ratio for participants with values above the 80th percentile relative to the rest of the participants, the 80th percentile
corresponding to values 79.7pg/mL or more for BNP.
‡Hazard ratio for participants with values below the 20th percentile relative to the rest of the participants, the 20th percentile
corresponding to values less than 24 poits in MMSE score.
# All parameters with p<100 in Table 1 were included in the multivariable model.  Because of mutual dependency, only one of the
lipid parameters, HDL cholesterol, was included. Similarly, only systolic blood pressure was included. Adjustment for age, body
mass index, New York Heart Association class I-II or III-IV, heart failure, systolic blood pressure, hypertension, previous myocardial
infarction, atrial fibrillation, stroke, diabetes, haemoglobin, high density lipoprotein, creatinine clearance, as well as adjustment for
MMSE in analysis for BNP and adjustment for BNP in analysis for MMSE.
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Figure 4. Age- and  sex-adjusted Cox proportional hazards survival  curves  for  total  and
cardiovascular  mortality  divided  by  B-type  natriuretic  peptide  (BNP)  and  Mini  Mental  State
Examination Test (MMSE) quintiles (I-V), separately, in the entire study population (n=499). (A)
BNP and total mortality (P for trend < .001); (B) MMSE and total mortality (P < .001); (C) BNP
and cardiovascular mortality (P < .001); (D) MMSE and cardiovascular mortality (P= .067). The
BNP quintiles were 3.2–17.0, 17.2–28.0, 28.2–45.3, 46.2–78.8 and 79.7–500 pg/mL. The MMSE
score quintiles were 18 to 23, 24 to 25, 26 to 27, 28 and 29 to 30 (Study IV)
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6 Discussion
6.1 METHODOLOGICAL CONSIDERATIONS
6.1.1 Risk markers for cardiovascular disease and cognitive dysfunction
Risk assessment is essential in clinical decision-making when directing resources,
weighing alternative management strategies and choosing the best course of treatment for
a patient. In the context of cardiovascular disease, risk stratification for the general
population can lead to, for example, better allocation of the limited coronary angiography
or echocardiography resources, or a more effective use of primary preventive medications
or other preventive interventions, such as smoking cessation, at the population level
(Hlatky et al. 2009).
A prospective cohort study is the best tool for estimating the power of a certain risk
marker in predicting the defined end-point in the population (von Elm et al. 2007). The
risk of a certain outcome over the follow-up is then measured and reported by using a
survival  curve  or  reporting  the  number  of  events  over  the  given  time  period.  The
statistical association of the risk-marker with a predefined end-point can be studied by
using logistic regression or the Cox proportional hazards model. (Harrell et al. 1996)
Logistic regression is preferred when the follow-up time is fixed and short, as was the case
in our analysis regarding the prognostic value of BNP concerning the occurrence of
dementia during the fixed follow-up period of five years. The Cox proportional hazards
model is more suitable when the follow-up period varies or is longer, as was the case in
our analysis of the effect of BNP and MMSE on mortality. (Harrell et al. 1996) Several
critical issues have to be considered when these statistical methods are used. Firstly, it is
essential that the number of outcome events over the follow-up period is sufficient. The
number of the events, not the size of the study population, is crucial when the significance
of a certain risk-marker is estimated. (Hlatky et al. 2009) In  the  present  study,  the  main
outcome measures were mortality and newly diagnosed dementias during the follow-up.
The number of patients who expired was 258 out of the 499 individuals in Study IV and
177 out of the 355 individuals in Study II, producing outcome numbers comparable or
superior to the events in similar types of studies with considerably larger populations
(Kelman et al. 1994; Bella et al. 2002; Redfield et al. 2003; Kistorp et al. 2005; Strandberg et
al. 2009).
  Secondly, the risk marker should offer information beyond the basic demographic
parameters and established risk markers (Hlatky et al. 2009). In the context of
cardiovascular disease, this means that any novel prognostic marker should improve the
prediction  in  addition  to  the  individual’s  age,  sex,  smoking  status,  blood  pressure,  lipid
levels and the possible presence of diabetes (Wilson et al. 1998; Roques et al. 2003). A
greater  number  of  outcomes  is  necessary  when  testing  the  prognostic  power  of  the  risk
marker together with previously defined risk markers compared to univariable analysis
(Harrell et al. 1996). We used the above-mentioned covariates routinely in the analysis
included in our study.
6.1.2 Study population
This thesis is based on the analysis of a well-defined, stratified population-based cohort of
elderly people in the area of Kuopio, eastern Finland, in 1998. The refusal rate was only
14%, which is very low when compared to other studies with a similar kind of approach.
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(Bassuk et al. 2000; Nguyen et al. 2003; Kistorp et al. 2005; Kardys et al. 2009) The
generalisability  of  the  results  among  the  Finnish  elderly  population  is  therefore
presumably  good.  The  study  was  carried  out  in  an  almost  exclusively  white  Caucasian
population, which limits the use of the results for other ethnic groups.
The present data was collected in 1998, thirteen years ago; the use of cardiovascular
medication among the elderly has changed since then (Hiitola et al. 2007) and the invasive
treatment of cardiovascular disease is more active today in comparison to the period of the
data collection (Scarborough et al. 2010). This type of limitation is inherent to all long-term
follow-up studies due to the continuous evolvement of medical treatment.
6.1.3 Study design
The purpose of the Kuopio 75+ study was originally to examine the clinical epidemiology
of diseases, especially those causing dementia. Therefore, the analyses of cardiovascular
morbidity  and  mortality  have  to  be  considered  secondary  in  nature.  In  our  study
population, the prevalence of heart failure (24.6%) and other cardiovascular conditions
was markedly greater than in most of the studies focused on the epidemiology of heart
failure (Kupari et al. 1997; Redfield et al. 2003). The diagnosis of heart failure was obtained
from medical records, which may have caused a degree of over-diagnosis. Nevertheless,
Eastern Finland is known for an exceptionally high cardiovascular disease burden
(Pyörälä et al. 1985).
Echocardiographies  were  carried  out  in  random  fashion  by  a  single  experienced
cardiologist (prof. Raimo Kettunen) unaware of other study results. The tissue Doppler
method allowing accurate measurement of diastolic dysfunction was not available at the
time. It would have been of interest to see the dependence of diastolic dysfunction on
HDL cholesterol and BNP, and its association with mortality, in this cohort of elderly
subjects. One strength of the study was that the diagnosis and classification of dementing
illnesses were made by an experienced neurogeriatrician (prof. Raimo Sulkava), and brain
imaging by means of CT or MRI was routinely used.
6.2 HIGH-DENSITY LIPOPROTEIN AND SYSTOLIC DYSFUNCTION
HDL cholesterol was found to be significantly associated with systolic function of the
heart,  while  BNP  showed  no  connection  to  echocardiographically  measured  ejection
fraction. The mechanism linking HDL cholesterol to systolic function is not clear. More
extensive coronary disease, caused by low HDL cholesterol, leading to cardiac ischemia
could serve as an explanation. Notably, the use of long-acting nitrates, a previous
myocardial infarction, and the presence of arteriosclerosis obliterans (ASO) or diabetes
were not significantly linked to systolic function. This could implicate that a mechanism
independent of coronary disease could partly explain the connection between HDL
cholesterol and systolic function.
Traditionally,  HDL is  known for  its  ability  to  remove excessive  cholesterol  from its
target organ, mostly the vascular system, and therefore to have an atheroprotective effect.
Apart from its cholesterol transport function, HDL has potent anti-inflammatory and
oxidation-preventing properties (Banka 1996; Sviridov et al. 2008). HDL also has an anti-
thrombotic and anti-adhesive effect on platelets and is known to protect endothelial
function by stimulating endothelial nitric oxide synthase (Sviridov et al. 2008). Oxidative
stress and endothelial dysfunction have been connected to heart failure and could partly
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explain the association between systolic function and HDL cholesterol (Bergamini et al.
2009).
There is accumulating evidence that the plasma concentration of HDL cholesterol is
not the only determinant of its atheroprotective capacity (Sviridov et al. 2008). The HDL
functionality, mostly independent of its concentration, is as important in determining the
atherogenic capacity of HDL. HDL contains many other lipids and proteins in addition to
cholesterol, and measuring the plasma HDL cholesterol concentration does not take into
account possible functional differences in HDL particles and therefore possibly
underestimates the true effect of HDL on systolic function (Vaisar et al. 2007).
Low total cholesterol is known to correlate with excess mortality in the elderly
population (Weverling-Rijnsburger et al. 1997). Additional mortality has been mainly due
to infectious diseases and neoplasms (Weverling-Rijnsburger et al. 1997). Cardiovascular
mortality has not been affected, implicating that low HDL cholesterol and its correlation
with systolic dysfunction is likely to be a separate issue from the previously-mentioned
one. In heart failure patients, low cholesterol also correlates with excess mortality
(Rauchhaus et al. 2003). Statin therapy has been associated with lower mortality –
regardless  of  lipid  levels  and  the  presence  or  absence  of  coronary  disease  in  a  large
epidemiological study (Go et al. 2006). The anti-inflammatory and anti-oxidative effects of
statins have been suggested to be the mechanisms of positive statin effect on cardiac
function (Sola et al. 2006). On the other hand, in two prospective randomised trials
studying the prognostic effect of rosuvastatin therapy on heart failure patients with
systolic dysfunction (Kjekshus et al. 2007) and patients with systolic or symptomatic
diastolic dysfunction (Tavazzi et al. 2008), no mortality benefit was seen.
6.3 B-TYPE NATRIURETIC PEPTIDE AND SYSTOLIC DYSFUNCTION
As expected, BNP levels were significantly higher, and a history of diabetes, significant
valvular disease, ASO and myocardial infarction more common among participants with
previously diagnosed heart failure, when compared with the rest of the study population.
In contrast, systolic dysfunction, measured by EF, was not significantly linked to BNP or
any other of these variables.  In an earlier study, with a similar type of setting conducted
on elderly individuals, BNP was found to associate with systolic dysfunction (Smith et al.
2000). Compared with the study mentioned, our study population was larger, the
recruiting of the intended cohort more successful, and the cardiovascular conditions and
medication were reported. It is possible that differences in these factors explain the
contradictory findings. It has been proposed that natriuretic peptides, BNP and NT-BNP
could be used as a screening test for cardiac systolic dysfunction in high-prevalence
populations, including the elderly (Alehagen et al. 2003; Heidenreich et al. 2004). The
prevalence of systolic dysfunction (defined as EF 45% or lower) in our general population
was 24% and, based on earlier data, it could have been expected that BNP would have
performed better in recognising patients with reduced EF. Significant valvular disease was
associated with BNP in our study population, whereas HDL cholesterol did not show any
association. Symptomatic heart failure in the elderly is predominantly caused by diastolic
dysfunction (Kupari et al. 1997) which, together with valvular disease, is likely the main
explanation  for  the  poor  link  between  BNP  and  systolic  dysfunction.  Furthermore,
diuretics and drugs influencing the RAA have a well-established moderating influence on
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blood BNP (Vuolteenaho et al. 2005), and their use may partly explain the lack of
association between BNP and ejection fraction.
6.4 INVERTED MITRAL INFLOW PATTERN AND TOTAL,
CARDIOVASCULAR AND NON-CARDIOVASCULAR MORTALITY
Inverted mitral inflow, defined as an E/A ratio of less than 0.75, was the strongest
predictor of mortality out of the measured echocardiographical parameters. Interestingly,
the prognostic value of an inverted mitral inflow pattern was mainly driven by its
association with non-cardiovascular mortality, with no significant connection to
cardiovascular mortality. Earlier studies on the prognostic value of inverted mitral inflow
pattern have been unanimous in their message: inverted mitral inflow has been a strong
predictor of mortality (Bella et al. 2002; Redfield et al. 2003; Kardys et al. 2009). The studies
have been carried out with younger populations with lower mortality rates. The only
study to report on total and cardiovascular mortality separately connected inverted E/A
with both end-points, but, interestingly, the connection to cardiovascular mortality was
not independent of covariates (Bella et al. 2002). It would be of great interest to revisit the
data of larger population-based studies to ascertain the possible connection of inverted
mitral inflow with non-cardiovascular mortality.
It would have been necessary to include either pulmonary vein inflow Doppler
measures or tissue Doppler measures to differentiate the truly normal mitral inflow from a
pseudonormal pattern, which is a sign of impaired ventricular relaxation with elevated
filling pressures. Therefore, participants with a “normal” mitral inflow pattern, E/A 0.75–
1.5, in this elderly general population with a high prevalence of cardiovascular disease
have to be considered to have indeterminate diastolic function. To the contrary, those with
E/A less than 0.75 have clearly abnormal diastolic function based on validated
classifications (Ommen et al. 2000; Oh et al. 2006). A high prevalence of participants with a
pseudonormal pattern could explain the higher levels of BNP among participants with
E/A 0.75–1.5. Furthermore, the use of diuretics, known for their lowering effect on BNP
(Vuolteenaho et al. 2005), was more common among participants with E/A < 0.75, but it
did not seem to explain the prognostic power of inverted mitral inflow in the
multivariable model (Table 2). The higher total mortality among participants with an
inverted  mitral  inflow  pattern  but  lower  BNP  levels,  and  the  higher  incidence  of  non-
cardiovascular causes of death during the follow-up, is somewhat unexpected and serves
as a ground for speculation backed up by other findings in the population.
Among populations of advanced age, the attenuation of the E/A ratio can be caused
by many mechanisms not related to heart failure (Finucci et al. 1996; Bossone et al. 1999;
Salerno et al. 2003; Gurudevan et al. 2007). The elderly often have an impaired ability to
sense thirst (Waldreus et al. 2010), and chronic dehydration is common among the elderly,
especially among cognitively impaired individuals (Morley 2002). Dehydration is known
to co-exist with malignancies (Price 2010). It decreases the filling pressure of the left
ventricle, which attenuates the E wave and, consequently, lowers the mitral E/A ratio.
Cognitive impairment and, in particular, dementive illnesses are known to have a
remarkable impact on prognosis (Kelman et al. 1994; Larson et al. 2004). In our study
population, various forms of dementia were significantly more common among
participants with an inverted mitral inflow pattern. Cholesterol metabolism has been
linked to cognitive decline in multiple studies (Kerola et al. 2011), and a recent analysis
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carried out among the HYVET study population connected a low level of HDL cholesterol
to a faster cognitive decline in a hypertensive elderly population (Peters et al. 2009). The
HDL cholesterol level was also significantly lower in our study among participants with
an E/A < 0.75. An inverted mitral inflow pattern is known to be more common among
individuals  with  chronic  lung  disease  or  chronic  pulmonary  embolism  (Bossone  et  al.
1999; Gurudevan et al. 2007) – in our population, there was a trend towards more
astma/COPD cases among participants with an E/A ratio of under 0.75. Liver failure is also
known to cause intravascular hypovolaemia, and an inverted mitral inflow pattern has
been shown to co-exist with liver cirrhosis (Finucci et al. 1996; Salerno et al. 2003).
Unfortunately, liver function was not measured in the present data.
These non-cardiovascular conditions could possibly explain the association of
inverted mitral inflow with excess non-cardiovascular mortality. In concordance with this
reasoning, one earlier study among the elderly using pulsed Doppler measures of
pulmonary venous flow for differentiating a pseudonormal from a normal mitral inflow
found that N-terminal ProBNP levels were lower among participants with an inverted
mitral inflow pattern when compared to counterparts with diastolic function classified as
normal based on mitral inflow (Alehagen et al. 2003). Importantly, E/A can be recorded
only when sinus rhythm is present, and participants with atrial fibrillation were excluded
from these analyses.
6.5 LEFT VENTRICULAR MASS, EJECTION FRACTION AND MORTALITY
The left ventricular mass index was a significant predictor of total mortality in the models
applied. This finding is in the line with several earlier larger population-based studies in
populations with varying age compositions (Levy et al. 1990; Gardin et al. 2001; Kardys et
al. 2009). As expected, the predicting power of left ventricular mass was due to its
association with cardiovascular mortality, whereas it showed no connection to non-
cardiovascular mortality.
Ejection fraction as a continuous parameter showed no association with mortality in
our  study.  This  finding  is  most  probably  due  to  a  lack  of  power,  since  previous  larger
population-based studies have found EF to predict both total and cardiovascular mortality
(Aurigemma et al. 2001; Devereux et al. 2003; Redfield et al. 2003; Wang et al. 2003), with a
single exception (Kardys et al. 2009).  Importantly, our study population demonstrated a
trend towards higher mortality among participants with severely reduced ejection fraction
(<35%).
6.6 BNP AND COGNITIVE DYSFUNCTION
We found BNP to be associated with all the measured cognitive endpoints: baseline
MMSE,  the  decline  oinf  the  MMSE  during  the  follow-up  and,  most  importantly,  new
diagnoses of dementing illnesses during the follow-up. Several previously known risk
markers for cognitive impairment, such as low educational level, age as well as
cardiovascular illnesses and risk markers, were associated with baseline MMSE, but none
of  these  were  linked  to  the  further  decline  in  MMSE  over  the  follow-up  in  this  elderly
population free of dementia at baseline; remarkably, BNP was the only variable to be
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connected with this outcome. The association between the decline in MMSE and BNP was
not  explained  by  the  commonly  known  confounding  factors  of  age,  sex,  total  years  of
education, depression or baseline MMSE.
The prevalence of dementia at baseline in the present study population was 22.8%,
being in concordance with previous data (Evans et al. 1989). Similarly, the high annual
mortality rate of 8.1% during the follow-up was expected in this elderly population. A
high level of natriuretic peptides and dementia are both known to associate with excess
mortality in the elderly (Jagger et al. 2000; Kistorp et al. 2005). The use of diuretics and
agents affecting the renin-angiotensin system, known also to lower the level of BNP, was
more common among participants with a higher level of BNP in the present study. Hence,
high  mortality  and  the  use  of  medication  affecting  the  BNP  level  might  even  have
attenuated the ability of BNP to predict cognitive decline.
HDL (but not total) cholesterol was associated with a low MMSE score at baseline,
but  it  did  not  predict  further  decline  in  cognitive  function  in  our  study.  This  is  in
concordance with earlier reports where lipid levels in middle-age, but not in later years,
were associated with future cognitive impairment (Notkola et al. 1998; Kloppenborg et al.
2008).  The existing literature supports the notion that the relation between blood pressure
and cognitive level is age-dependent. In studies conducted on middle-aged populations,
hypertension has predicted cognitive impairment (Launer et al. 2000; Kivipelto et al. 2005),
but the role of blood pressure in cognitive decline in the elderly is less clear: some studies
have (Yoshitake et al. 1995) but most have not (Posner et al. 2002; Kloppenborg et al. 2008)
reported an association between blood pressures and cognitive decline. On the contrary, in
late-life cross-sectional studies low blood pressure has been constantly associated with
poor cognitive function (Guo et al. 1996; Kloppenborg et al. 2008). In our study, there was
a trend towards an association between low diastolic pressure and new onset of
dementias. Interestingly, a diagnosis of hypertension was associated with a lower
incidence of dementia in the follow-up, independently of previously known risk factors of
dementia. This may be explained by the more common use of antihypertensive medication
among participants who have been diagnosed with hypertension (P<.001 for all classes of
antihypertensive medication, separately, data not shown). This is backed up by earlier
epidemiological studies in which the use of antihypertensive medication has been
associated with a lower incidence of cognitive decline (Guo et al. 1999; Veld et al. 2001; Li
et al. 2010). The analysis from the extensive database of 819,491 predominantly male
individuals indicated that ACE inhibitors offer additional benefit when compared to other
antihypertensive drugs in terms cognitive measures (Li et al.). An analysis from the
Cardiovascular Health Study indicated that the use of ACE inhibitors crossing the blood
brain barrier might be associated with better outcome in terms of cognitive function (Sink
et al. 2009). In our study population, 59 participants used ACE inhibitors, and there was a
trend towards a lower frequency of diagnosed dementia among ACE inhibitor users
(OR=0.476; p=0.100). The data is too limited for further analysis between different types of
ACE inhibitors.
So far, randomised placebo-controlled studies with antihypertensive medications
have included cognitive measures as a secondary end-point, and the results have been
conflicting (Applegate et al. 1994; Forette et al. 1998; Skoog et al. 2005; Peters et al. 2008;
Anderson et al. 2011)
Blood pressure amongst the aged may not be as good a marker of cardiovascular
morbidity as in younger populations, since it is attenuated by many factors common in the
elderly population, such as dehydration, heart failure, atrial fibrillation and aortic stenosis.
Therefore, it is possible that the heart and cardiovascular system are under stress and
predispose to cognitive impairment even if blood pressure is not elevated. It is also
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possible that elevated blood pressure in the elderly is an indicator of robust cardiac pump
function, which in turn is required for adequate perfusion through an aged vasculature to
various organ systems, including the brain.
BNP is a marker of cardiac – especially left ventricular – pump function and has been
linked to both cardiovascular and total mortality in the general elderly population
(Kistorp et al. 2005). In heart failure patients, high levels of BNP have been linked to
cognitive dysfunction in a small (n=60) cross-sectional trial. Heart failure, linked to BNP,
did not predict cognitive decline or dementia in the present data. The explanation for the
ability of BNP to predict forthcoming cognitive impairment is not clear. In our study, the
history of stroke was taken into account, and it did not predict cognitive decline as BNP
did (Table 2). The predictive value of BNP was further tested in subgroup analyses in
participants with no history of heart failure or stroke, separately, with no material change
in results. High levels of BNP are associated with endothelial dysfunction, and this
phenomenon has recently been linked to cognitive function (Chong et al. 2004).
As expected, the majority of the participants with dementia in our study population
were diagnosed with Alzheimer’s disease. BNP was associated with multiple baseline
parameters, such as age and low BMI, previously found to be associated with Alzheimer’s
disease. MR-proANP is a stable form of the N-terminal fragment of proatrial natriuretic
peptide.  In  line  with  the  studies  on  the  association  of  MR-proANP  with  the  presence  of
dementia and the predictive value for future dementia by Buerger et al. (Buerger et al.
2009; Buerger et al. 2011), BNP, a potent vasodilatator, was significantly associated with
both new cases of Alzheimer’s disease and vascular dementia in a subgroup analysis. The
association with vascular dementia appeared to be even stronger than with Alzheimer’s
disease, but the results with a small number of vascular dementia cases (N=10) should be
interpreted with caution.
Despite the contradictory results in the elderly regarding the association between
hypertension and dementia, it is important to remember that treatment of hypertension
has been highly efficacious also among elderly patients in preventing mortality and
cardiovascular events. Therefore, enough evidence exists to guide pharmacological
treatment in older patients for hypertension and dyslipidaemia, even though the evidence
is not sufficient in terms of dementia prevention. Aggressive reduction of blood pressure
should be avoided in the very old, given the unwarranted negative cognitive
consequences.
6.7 B-TYPE NATRIURETIC PEPTIDE AS A PREDICTOR OF MORTALITY IN
THE ELDERLY
BNP was a powerful, independent predictor of total and cardiovascular mortality, as
expected based on the results on earlier studies addressing the issue (Wallen et al. 1997;
Kistorp et al. 2005). Several recent studies have suggested that cardiovascular morbidity
and cognitive dysfunction are closely connected among the elderly (Morris et al. 2001;
Iadecola et al. 2008; Kloppenborg et al. 2008; Buerger et al. 2011). In the present study –
even after adjusting for cognitive function measured by the MMSE score – BNP remained
a  robust  predictor  of  total  and  cardiovascular  mortality.  Considering  the  known
association with heart failure, BNP was also studied in the subgroup of participants who
had no previously diagnosed heart failure, with no material changes in the results.
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Altered levels of BNP are known to be associated with several cardiovascular
conditions,  such  as  hypertension,  atrial  fibrillation,  history  of  myocardial  infarction  and,
particularly, heart failure caused by systolic or diastolic cardiac dysfunction (Vuolteenaho
et al. 2005). Diastolic heart failure and asymptomatic cardiac dysfunction are exceedingly
common among the aged (Redfield et al. 2003), and they are likely to explain some of the
good predictive value of BNP on mortality in an elderly population. We used clinical
manifestations of the above-mentioned diseases as covariates in our multivariable
analysis, but BNP consistently remained a significant variable in the models. Furthermore,
the median BNP level in our study was remarkably low as compared to patients with
clinical heart failure. These findings underscore the predictive importance of even modest
increases in BNP.
Traditional cardiovascular risk markers such as hypertension, dyslipidaemia, and
obesity are known to lose much if not all of their prognostic power when measured in the
elderly (Oates et al. 2007; Takata et al. 2007). Low blood pressure and low cholesterol have
often served as predictors of mortality when studied among the aged population. Both of
these parameters also had the inverse association with mortality in our study, even though
low total cholesterol only in a univariable model. Systemic blood pressure is attenuated by
several conditions frequently found in the elderly population, such as heart failure, atrial
fibrillation, aortic stenosis and dehydration. All of these derangements are associated with
increased mortality, deteriorating the prognostic value of hypertension among elderly.
Thus, it is possible that the heart and cardiovascular system is under stress – as evident in
the  relative  increase  in  the  BNP  level  –  even  in  the  case  of  normal  or  even  low  blood
pressure. This is also a putative mechanism for antihypertensive medication, which is
protective against dementia even in the presence of normal blood pressures.
A history of atrial fibrillation, symptomatic heart failure, myocardial infarction or
stroke were more common among the individuals who expired; only a history of stroke
had  any  connection  with  mortality  in  the  multivariable  models.  In  line  with  previous
studies, a high NYHA class and diabetes were associated with cardiovascular mortality.
This corresponds with earlier mortality studies conducted in the elderly: the quantitative
characteristics of disease severity, such as NYHA class, BNP or the MMSE score, are
stronger determinants of prognostic impact than the sheer existence of the condition (Fried
et al. 1998). CRP, a marker of inflammation and an extensively studied cardiovascular risk
marker, has also performed worse in prognostic studies conducted in the elderly
(Strandberg et al. 2000; Kistorp et al. 2005), while BNP as a direct marker of left ventricular
stretch and cardiovascular stress has kept its impact as a prognostic marker also in various
studies among the aged population (Wallen et al. 1997; Kistorp et al. 2005).
6.8 MMSE SCORE AND MORTALITY
In  our  population,  the  MMSE  score,  both  as  a  continuous  variable  and  using  the  cut-off
point of 24, was a significant predictor of total mortality in all the models. In a model
including other factors associated with mortality, its individual impact on mortality was
only of moderate value. The predictive value of an MMSE score of less than 24 points, as
studied separately and in an age- and sex-adjusted model, agreed with recently published
data by Strandberg et al. (Strandberg et al. 2009) in a similar type of setting. In a
multivariable model, the predictive value of this variable was somewhat reduced in our
data, possibly reflecting the more extensive use of confounding variables in the survival
model.
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To avoid the strong prognostic implications of a diagnosis of dementia, we
performed a sub-analysis after excluding the 45 individuals with dementia (all with
MMSE 18). The value of the MMSE score was somewhat attenuated but not abolished
with regard to total mortality, when the patients with an established compromised
prognosis were excluded. This suggests that the prognostic importance of the MMSE score
is also conveyed by other pathways than dementia. These additional mechanisms may
include, for example, difficulties in engaging in health promoting activities, seeking
medical advice or using the prescribed medication.
Severely reduced cognitive function, defined as an MMSE score of less than 18 points,
and known dementing illness are evidently associated with severely compromised
prognosis. The definition of mild cognitive impairment has varied significantly and a wide
range of diagnostic approaches has been recommended (Gauthier et al. 2006). Larger
epidemiological studies on the prognostic value of mild cognitive impairment have relied
often on MMSE score as a diagnostic measure (Bassuk et al. 2000; Nguyen et al. 2003;
Strandberg et al. 2009), and the results have been contradictory. Studies using an MMSE
score of 18–23 as a definition of mild cognitive impairment have found this criterion to be
a significant predictor of mortality (Bassuk et al. 2000; Strandberg et al. 2009), while a
study employing another measure of cognition, the Short Portable Mental Status
Questionnaire, showed no predictive value for mild cognitive impairment (Stump et al.
2001). One study suggested that the association is apparent only in individuals aged less
than 80 years (Bassuk et al. 2000). The present data suggest an association with the MMSE
score and mortality also among those beyond 80 years of age (data not shown).
6.9 MMSE SCORE AND CARDIOVASCULAR MORTALITY
 Cognitive dysfunction has been associated with heart failure due to systolic and diastolic
dysfunction (Cacciatore et al. 1998; Suwa et al. 2009), and cognitive decline has been
shown to predict mortality in heart failure patients (Zuccala et al. 2003). The failure of
traditional cardiovascular risk markers for the elderly, and the accumulating evidence on
the association between cardiovascular burden and cognitive dysfunction have led to the
hypothesis that the MMSE score might hold additional predictive value for cardiovascular
mortality (Strandberg et al. 2009). Our data suggest that mild cognitive impairment as
defined by an MMSE of 18–23 is associated with cardiovascular mortality when studied
separately or in a sex- and age-adjusted model. In a multivariable model with known
cardiovascular risk markers, with or without BNP, the MMSE score did not provide any
additional prognostic information.
6.10 FUTURE PERSPECTIVES
Epidemiological studies on the elderly population are challenging due to several reasons.
In studies among younger populations confounding illnesses and medications are
seemingly rare,  and individuals carrying/using them can be excluded, allowing for more
clear conclusions about the association of the risk factor and the outcome studied. In the
elderly population multiple pathological conditions are present and the use of different
medications is far more common. The physiological changes associated with aging and
pathological changes connected to cognitive decline further add to the complexity of the
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studies. Our finding concerning the association of the mitral valve inflow pattern with
non-cardiovascular mortality and the presence of dementive illness has not been reported
previously.  This  finding  should  be  confirmed  in  other  studies  carried  out  in  elderly
populations, and the predictive power of mitral inflow concerning non-cardiovascular
mortality should also be analysed in population studies among younger individuals.
Studies tackling the most interesting aspect of daily practice, whether the occurrence
of a dementive illness can be postponed or whether the prognosis of an already diseased
person can be improved by influencing cardiovascular risk burden, have been rare. Such
data  would  also  disclose  whether  an  individual  cardiovascular  risk  factor  bears  a  direct
pathophysiological role in the development of cognitive impairment or whether it is
merely  a  bystander  reflecting  an  underlying  process  responsible  for  the  development  of
dementia.  Targeting  this  major  perspective  requires  the  launching  of  interventional
studies with cognitive changes as primary end points, while the past analyses have almost
exclusively used cognitive markers as secondary or, more frequently, tertiary end points.
If  the  occurrence  of  a  dementing  illness  can  be  delayed  even  by  one  year,  it  would
constitute a remarkable difference in the suffering of the patients and their families, not
forgetting the impact on economical costs at the society level. Therefore, definitive
randomised double-blind studies are needed, even though funding such trials may be
problematic, since the cardiovascular drugs most often applied in risk factor control are
relatively  inexpensive.  Our  finding  about  the  connection  between  cognitive  dysfunction
and  BNP  adds  to  the  body  of  evidence  that  cardiovascular  morbidity  and  stress  also
significantly affect cognitive decline in the elderly population. Future studies investigating
the  effect  of  antihypertensive  therapy  on  cognitive  function  in  the  elderly  should  clarify
whether the concomitant decrease in BNP stratifies the risk of cognitive impairment. If so,
BNP determination might identify the patients who would potentially benefit from
antihypertensive therapy in the prevention of dementia.
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7 Conclusions
Based on the findings of the present study, the following conclusions in a population aged
75 or more can be made:
1. In the overall study population and in the subgroup of participants with no
previous heart failure, HDL cholesterol, but not BNP, shows significant correlation
with left ventricular systolic dysfunction.
2. An echocardiographically measured inverted mitral inflow pattern is a robust
predictor of total and non-cardiovascular mortality, with no significant connection
to cardiovascular mortality.
3. BNP  is  an  independent  harbinger  of  cognitive  decline  and  the  incidence  of  new
onset of dementia. This is grounds for testing the impact of antihypertensive
treatment in the prevention of cognitive impairment in those with elevated BNP.
4. BNP, a measure of cardiovascular burden, and an MMSE score of 18–23, an
indicator of mild cognitive impairment, are both independent predictors of total
mortality. BNP, but not an MMSE score of 18–23, is independently associated to
cardiovascular mortality. BNP and MMSE score may potentially be useful in
screening patients for an elevated risk of mortality.
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The impact of B-type natriuretic 
peptide (BNP), the Mini Mental State 
Examination score and echocar-
diographical measures on cognitive 
decline and mortality in the elderly 
general population was evaluated in 
the present study. While traditional 
cardiovascular risk markers failed to 
predict cognitive decline, BNP, mark-
er of the burden of the heart ventri-
cle, was solidly associated with cog-
nitive decline and mortality. Future 
studies investigating the  effect  of  
antihypertensive  therapy  on  cogni-
tive  function  in  the  elderly  should  
clarify whether the concomitant 
decrease in BNP stratifies the risk of 
cognitive impairment.  
